Coagulation

Jason Ryan, MD, MPH

Thrombus Formation



Vasoconstriction

- 1st line of defense against bleeding
- Occurs in response to endothelial damage
- Key mediator: **endothelins**
  - Proteins
  - Potent vasoconstrictors
  - Released by **endothelial cells** near site of damage
  - Endothelin receptor blockers used in pulmonary hypertension

Coagulation Factors

- Proteins synthesized in **liver**
- Soluble in plasma
- Activate when triggered by endothelial damage
- Form an insoluble protein: Fibrin
- Fibrin mesh prevents blood loss

Coagulation Factors

- Most circulate as inactive enzymes (zymogens)
- Many activate to become **serine proteases**
  - Serine: amino acid
  - Protease: cleaves proteins
  - Serine protease: protein cleavage enzyme, contains serine



Serine

Coagulation Cascade

- **Sequential** activation of clotting factor zymogens
- Constant low level of activation in serum
- **Amplification** occurs with endothelial damage
- Leads to **fibrin generation**

Coagulation Cascade



Joe D/Wikipedia

Coagulation Cascade

- Center of cascade is activation of X → Xa
- Xa converts prothrombin (II) → thrombin (IIa)
- Thrombin (IIa): Fibrinogen (I) → fibrin (Ia)
- Fibrin forms plug to stop bleeding
- **Activation X → Xa makes fibrin**

Coagulation Cascade



Coagulation Cascade



Tissue Factor

Thromboplastin

- **Glycoprotein**
- Constitutively expressed in **sub-endothelial** cells
- Not expressed by endothelial cells
- No significant contact of with circulating blood
- Exposed by endothelial damage
- **Major activator of coagulation system**
- Basis for **Prothrombin Time and INR**
  - Tissue factor added to blood sample
  - Time to form clot = PT

Coagulation Cascade

- Primary event: Exposure of tissue factor
- Interacts with factor VII → VIIa
- **TF:VIIa activates Xa**

TF:VIIa

Coagulation Cascade



Thrombin

- **Thrombin (IIa) makes more thrombin**
- Can activate cascade (positive feedback)
  - **Factor V** → Va
  - **Factor XI** → XIa
  - **Factor VIII** → VIIIa
- Factor XIa activates **IX → IXa**
  - IX uses VIIIa as a co-factor
- IXa can also activate Xa
  - More amplification



Coagulation Cascade



Factor VIII

- Produced in endothelial cells (not the liver)
- Circulates bound to **von Willebrand Factor**
  - vWF critical for platelet aggregation
  - vWF produced by endothelial cells and megakaryocytes
  - Binding to vWF increases VIII plasma half life
- Released from vWF in response to vascular injury
  - Vascular injury → ↑ thrombin → becomes VIIIa

VIII—vWF

Multicomponent Complexes

- Two complexes for conversion X → Xa
- Three components bound together:
  - Active clotting factor functioning as enzyme
  - Co-factor
  - Substrate
- Require **phospholipids and calcium**
  - Phospholipid: Occur on surfaces of cells
  - TF-bearing cells or platelets
  - Calcium: Co-factor

Multicomponent Complexes

- Extrinsic Xase
  - Phospholipid: TF-bearing cells
  - Enzyme: **Factor VIIa**
  - Co-factor: Tissue factor
  - Substrate: Factor X



Multicomponent Complexes

- Intrinsic Xase
  - Phospholipid: Platelets
  - Enzyme: **Factor IXa**
  - Co-factor: Factor VIII (VIIIa)
  - Substrate: Factor X



Coagulation Cascade



Coagulation Cascade



Calcium

- Factor IV
- Required for clot formation
- Activated platelets release calcium
- EDTA binds calcium in blood samples
- Prevents clotting

Tannim101/Wikipedia-

Factor XIII

- **Crosslinks** fibrin
- Stabilizes fibrin plug
- Absence of XIII → inadequate clot formation
- Requires **calcium** as co-factor
- Activated by thrombin (IIa) formation

Coagulation Cascade



Coagulation Cascade



Factor XII

Hageman factor

- Can activate factor XI (XIa)
- Physiologic significance unclear
- Important for testing of coagulation system
- Activated by **contact** with negatively charges
- Factor XII → XIIa via contact with silica
- Basis for **partial thromboplastin time (PTT)**



Coagulation Cascade



Coagulation Cascade



Coagulation Cascade



Coagulation Cascade



Activated Partial Thromboplastin Time (PTT)

Add Plasma to (-) charge substance (silica)
Time to form clot

Coagulation Cascade

Prothrombin Time (PT)

Add Plasma to TF

Time to form clot



Intrinsic Pathway

Contact Pathway

- Requires **kinins** for normal function
- Kinins = **peptide** hormones/signaling molecules
- Short half lives
- Circulate as inactive precursors: kininogens
- Activated by kallikreins
- Kinins **link coagulation with inflammation**

Intrinsic Pathway

Kinin System

- **Bradykinin**
  - Vasodilator
  - Increases vascular permeability
  - Pain
- Degraded by angiotensin converting enzyme (ACE)
  - **ACE inhibitors** can raise bradykinin levels
  - Dangerous side effect: **angioedema**
- Also degraded by C1 inhibitor (complement system)
  - C1 inhibitor deficiency → **hereditary angioedema**

Intrinsic Pathway

Factor XII

- **Activates clotting and produces bradykinin**
- Requires PK, HMWK for normal function



Prekallikrein Deficiency

- Rare condition
- Results in **markedly prolonged PTT**
- **XII cannot activate normally**
- No bleeding problems



Kinin System

Key Points

- Activated by factor XII
- Link between coagulation and inflammation
- Bradykinin
  - ACE inhibitors
  - Hereditary angioedema
- Prekallikrein Deficiency: ↑PTT

Coagulation Inhibitors

- Important **deactivators** of coagulation
  - Antithrombin III
  - Proteins C and S
  - Tissue factor pathway inhibitor

Antithrombin III

- Serpin (inhibitor of serine proteases)
- Inhibits serine proteases: factors II, VII, IX, X, XI, XII
- Produced by liver
- Activated by endothelium
  - Endothelium makes heparan sulfate molecules
  - Activate antithrombin
  - Basis for role of **heparin drug therapy**
- Deficiency: Hypercoagulable state

Proteins C and S

- Glycoproteins synthesized in liver
- Protein C: zymogen
- Active form: activated protein C (APC)
- APC primarily inactivates factors **Va and VIIIa**

Proteins C and S

- Protein C activated by **thrombomodulin**
  - Cell membrane protein
  - Found on **endothelial cells**
- Thrombomodulin binds thrombin
  - Complex activates protein C to APC

Proteins C and S

- APC requires **protein S as co-factor**
- Protein S circulates in active form (not a zymogen)



TFPI

Tissue factor pathway inhibitor

- **Inactivates Xa** via two mechanisms
  - Directly binds Xa
  - Binds TF/FVIIa complex → prevents X activation
- Plasma levels increased with heparin administration
  - May contribute to antithrombotic effect

Plasminogen and Plasmin

- Plasminogen synthesized by liver (zymogen)
- Converted to active enzyme: **plasmin**
- Main role of plasmin is breakdown of fibrin
  - Broad substrate specificity
  - Also degrades clotting factors, fibrinogen

Plasminogen Activators

- **Tissue plasminogen activator (tPA) and urokinase**
  - Synthesized by endothelial and other cells
  - Used as drug therapy for **acute MI and stroke**
  - **Streptokinase**: Streptococcal protein; activates plasminogen

FDPs and D-dimer



FDPs and D-dimer

- Fibrinogen has two domains: E (central) and D (side)
- Crosslinking of fibrin (XIII) creates E linked two Ds



Mpt-matthew/Wikipedia

FDPs and D-dimer



- D-dimer is a special type of FDP
- Presence of D-dimers indicates **clot breakdown**
  - Breakdown of ***crosslinked*** fibrin from XIII
  - Elevated D-dimer used for diagnosis of DVT/PE



FDPs and D-dimer



- ↑ FDPs seen in breakdown of **clot**
- Also seen in absence of clot from **fibrinogen breakdown**
- Plasmin can convert fibrinogen → FDPs
- FDPs indicate plasmin activity only
- Not necessarily clot breakdown



Primary Fibrinolysis

- Rarely phenomena: **Plasmin overactive**
- Causes ↑ **FDP** with ***normal D-dimer***
  - "Hyperfibrinolysis"
  - Plasmin breakdown of fibrinogen (not fibrin) → FDPs
  - No clot or crosslinked fibrin → No d-dimers
  - **Plasmin can deplete clotting factors**
  - Increased PT/PTT with bleeding (like DIC)
  - Prostate cancer: release of urokinase
  - Cirrhosis: Loss of alpha2 antiplasmin from liver

FDPs and D-dimer

Key Points

- **Clot breakdown**: FDPs and D-dimers
- **Hyperfibrinolysis**: FDPs with normal D-dimer levels
- ↑ D-dimer used to diagnosis thrombotic disorders
- Elevated levels seen in DVT/PE
  - Sensitive but not specific
  - Elevated in many other disorders

Vitamin K

- Required for synthesis of many clotting factors
  - "Vitamin K dependent clotting factors"
- Vitamin K dependent factors: II, VII, IX, X, C, S
- Vitamin K deficiency: **bleeding**
- **Warfarin**: Vitamin K antagonist

Gonegonegone /Wikipedia

ESR

Erythrocyte Sedimentation Rate

- Rate of RBC sedimentation in test tube
  - Normal 0-22 mm/hr for men; 0-29 mm/hr for women
- Increased in **inflammatory conditions**



MechESR/Wikipedia

ESR

Erythrocyte Sedimentation Rate

- ESR increased by **"acute phase reactants"** in plasma
  - Serum proteins that rise in inflammation or tissue injury
  - Driven by cytokines
  - Most come from liver
- Key acute phase reactants
  - **Fibrinogen**
  - Ferritin
  - C-reactive protein (binds bacteria; activates complement)

Platelet Activation

Jason Ryan, MD, MPH

Thrombus Formation



Platelets

- Small cells derived from **megakaryocytes**
- Do not contain a nucleus
- Short lifespan: about 8-10 days
- Production regulated by **thrombopoietin** (TPO)
  - Glycoprotein produced mostly in liver



Graham Beards/Wikipedia

Platelets

- Aid in hemostasis after vascular injury
- Circulate in “inactive” form
- Can “activate” due to:
  - Endothelial injury
  - Stimuli from other activated platelets
- Activated platelets **seal damaged vessels**

Platelets Actions

- **Adhesion** to sub-endothelium
- **Aggregation**: Platelet-platelet binding
- **Secretion**: Release of granule contents
- Net result: Seal openings in vascular tree



Von Willebrand Factor

- Large **glycoprotein**
- Synthesized by endothelial cells and **megakaryocytes**
  - Stored in **Weibel–Palade bodies** in endothelial cells
- Present in platelets (stored in **alpha granules**)
- Some found in plasma
- Released on vascular injury
  - Activated platelets degranulate
  - Endothelial cells release vWF

Von Willebrand Factor

- Several roles in hemostasis
- #1: Carrier protein for **factor VIII**
  - Factor VIII released in presence of thrombin (VIIIa)
- #2: **Binds platelets** to damaged endothelium
- #3: Binds activated platelets together (aggregation)

VIII—vWF

Membrane Glycoproteins

- Glycoproteins (amino acids and glucose molecules)
- Found on surface of platelets
- Interact with other structures/molecules
- Important for hemostasis
- GPIb, GPIIb/IIIa

Platelets Actions

- **Adhesion** to sub-endothelium
- **Aggregation**: Platelet-platelet binding
- **Secretion**: Release of granule contents



Platelet Adhesion

- Vascular damage: **exposure of collagen**
- Subendothelial collagen **binds vWF**
- vWF **binds GPIb** on platelets



Platelet Aggregation

- Mediated by **GPIIb/IIIa receptor**
  - Most abundant surface receptor on platelets
- Platelet activation → GPIIb/IIIa changes conformation
  - Becomes capable of binding
  - Will not bind when platelets are inactive
  - "Inside-out" signaling (cell activity → altered receptor)



Platelet Aggregation

- GPIIb/IIIa binds **fibrinogen or vWF**
- Links platelets together (aggregation)
- Basis for **IIB/IIIA receptor blocking drugs**

Platelet Secretion

- Platelets activated by:
  - Binding to subendothelial collagen
  - Stimulation by activating substances
- Secretion of stored activators → more activation



Platelet Granules

- Two types of platelet granules: **alpha** and **dense**
- Contents promote hemostasis
- **Released on activation** by:
  - Platelet binding to collagen
  - Granule contents from other platelets



Dr Graham Beards/Wikipedia

Platelet Granules

- **Alpha** granules (most abundant)
  - Fibrinogen
  - von Willebrand factor
  - platelet factor 4
- **Dense** granules
  - ADP
  - Calcium
  - Serotonin



Dr Graham Beards/Wikipedia

Platelet Factor 4

PF4

- Released from **alpha** granules
- Binds to endothelial cells
- Numerous biologic effects described
- **Heparin induced thrombocytopenia**
  - Rare, life-threatening effect of heparin administration
  - Antibodies formed to PF4 complexed with heparin
  - Antibodies bind PF4-heparin → platelet activation
  - Diffuse thrombosis
  - Low platelets from consumption

Serotonin



- Stored in **dense** granules
- Released on platelet activation
- Basis for **serotonin release assay**
  - Diagnostic test for HIT
  - Donor platelets radiolabeled with ^{14}C-serotonin
  - Patient serum and heparin added
  - HIT antibodies → excessive serotonin release

Adenosine Diphosphate

ADP

- Released from **dense** granules
- Also released by red blood cells when damaged
- Binds to two G-protein receptors: $P2Y_1$ and $P2Y_{12}$
- Binding leads to ↓ cAMP formation
  - ↑ cAMP blocks platelet activation
  - **Phosphodiesterase inhibitors** → ↑ cAMP

Adenosine Diphosphate

ADP

- $P2Y_1$
  - Calcium release, change in platelet shape
- $P2Y_{12}$
  - Platelet degranulation, ↑ aggregation
- Many **$P2Y_{12}$ receptor blocking drugs**
  - "ADP receptor blockers"
  - Inhibit platelet activity
  - Clopidogrel, prasugrel, ticlopidine, ticagrelor

Thromboxane A2

TXA2

- Powerful **platelet activator**
- TXA2 receptors found on platelets
- Basis for aspirin therapy

Shizhao/Wikipedia

Thromboxane A2

TXA2

- Lipids in cell membranes → arachidonic acid (AA)
  - Enzyme: phospholipase A2
  - Occurs in endothelial cells near damaged endothelium
  - AA released at sites of vascular injury
  - Also stored in platelets
- AA converted by platelets to TXA2
  - Enzyme: Cyclooxygenase (COX)
- **Aspirin**: Inhibits COX → ↓ TXA2 → platelet activation

Bleeding Time

- Test of **platelet function**
- Small cut to patient's arm
- Filter paper applied/removed until bleeding stops
- Rarely done in modern era

Crystal/Flikr

Hypercoagulable States

Jason Ryan, MD, MPH

Hypercoagulable States

- Predisposition to venous or arterial thrombi
- Often DVT/PEs ("Venous thromboembolism")
- Sometimes arterial thrombosis
  - Stroke
  - Myocardial infarction
  - Ischemic limb

Virchow's Triad

- **Endothelial damage**
  - Endothelium makes numerous natural anticoagulants
  - Nitric oxide, prostaglandins, antithrombin, tPA, APC
- **Stasis of blood**
  - Normal blood flow prevents pooling of clotting factors
- **Hypercoagulability**
  - Conditions that increase clot formation



Hypercoagulable States

- **Post-op**
  - Hypercoagulable (inflammation from surgery)
  - Stasis (immobile)
  - Endothelial damage (surgery)
- Fall/Hip Fracture/Trauma
  - Hypercoagulable (inflammation from trauma)
  - Stasis (immobility)
  - Endothelial damage (trauma)
- Long plane flights
  - Stasis (immobility)



Wikipedia/Public Domain

Hypercoagulable States

- **Malignancy**
  - Some tumors produce pro-coagulants (i.e. tissue factor)
  - Adenocarcinomas: some data that mucin is thrombogenic
- Normal cells may produce pro-coagulants
  - Reaction to presence/growth of tumor
- Decreased activity, surgery, bed rest

Public Domain

Hypercoagulable States

- **Pregnancy**
  - Probably evolved to protect against blood loss at delivery
  - Many clotting factor levels change
  - Increased fibrinogen
  - Decreased protein S
  - Fetus also obstructs venous return → DVTs common
- Oral contraceptive pills (OCPs)
  - Estrogen increases production coagulation factors

Hypercoagulable States

- **Elevated homocysteine** (amino acid)
- Associated with **arterial and venous** clots
- High levels may cause:
  - Endothelial injury
  - Activation of some clotting factors



- Elevated levels caused by:
  - Folate/B12/B6 deficiency
  - Homocystinuria (cystathionine beta synthase deficiency)
- Levels lowered by **folate**
  - Most clinical trials of folate did not show benefit

Hypercoagulable States

- **Nephrotic syndrome**
  - Multiple mechanisms
  - Loss of anti-clotting factors in urine (ATIII)



Holly Fischer/Wikipedia

Hypercoagulable States

- **Smoking**
  - Associated with atherosclerosis and MI/Stroke
  - Some data linking smoking to DVT/PE
  - Evidence that smoking increases fibrinogen levels

Pixabay/Public Domain

Inherited Thrombophilia

- Inherited hypercoagulable states
- Genetic tendencies to **VTE**
- Most involve coagulation pathway defects
- All associated with venous clots (DVT/PE)

Hypercoagulable Condition
Factor V Leiden Mutation
Prothrombin gene mutation
Antithrombin deficiency
Protein C/S deficiency

Factor V Leiden Mutation

- Named for Leiden, Netherlands
- Abnormal **factor V**
- Not inactivated by **activated protein C (APC)**
- Factor V remains active longer → hypercoagulability



Factor V Leiden Mutation

- **Point mutation in factor V gene**
  - Guanine to adenine change
- Result: Single amino acid change
  - Arginine to glutamine substitution
  - Position 506 in factor V

Prothrombin Gene Mutation

- **Prothrombin 20210** gene mutation
  - Guanine to adenine change in prothrombin gene
  - Occurs at nucleotide 20210
- Heterozygous carriers: 30% ↑ prothrombin levels



Antithrombin III Deficiency

- Inherited deficiencies due to gene mutations
- Acquired deficiencies:
  - Impaired production (liver disease)
  - **Protein losses (nephrotic syndrome)**
  - Consumption (DIC)
- Classically presents as **heparin resistance**
  - Escalating dose of heparin
  - No/little change in PTT

Protein C or S Deficiency

- Protein C: associated with **warfarin skin necrosis**
- Initial warfarin therapy → ↓ protein C (short half life)
- If protein C deficient → marked ↓ protein C
- Result: **thrombosis of skin tissue**
- Large dark, purple skin lesions



Antiphospholipid Syndrome

- Caused by antiphospholipid **antibodies**
- Occur in association with **lupus** or as primary disease

Antiphospholipid Syndrome

- Three important clinical consequences of antibodies
- "Antiphospholipid syndrome"
  - #1: Increased risk of **venous and arterial thrombosis**
    - Most commonly DVT
    - Also CNS: stroke
    - **Recurrent fetal loss**
  - #2: **Increased PTT**
  - #3: **False positive** syphilis (RPR/VDRL)

Antiphospholipid Syndrome

- **Anti-cardiolipin**
  - False positive RPR/VDRL
  - Syphilis also produces these antibodies
- **"Lupus anticoagulant"**
  - Interferes with PTT test (silica activation of XII)
  - False elevation
- **Anti-β2 glycoprotein**

Antiphospholipid Syndrome

Antibody Detection

- **Anti-cardiolipin, Anti-β2 glycoprotein**
  - Enzyme-linked immunosorbent assay (ELISA) testing
- **"Lupus anticoagulant"**
  - Detected indirectly through coagulation assays

Lupus Anticoagulant

Coagulation cascade requires phospholipids



Lupus Anticoagulant

PTT Testing

- Lupus anticoagulant binds phospholipid → ↑ PTT



Lupus Anticoagulant

Mixing Study

- Can show presence of lupus anticoagulant (inhibitor)



Lupus Anticoagulant

Mixing Study

- Clotting factor deficiency: PTT corrects to normal
- Clotting factors ~50% normal → normal PT/PTT



Hemophilia
↓ Clotting Factors
↑ PTT

Normal
Serum

50% VIII
Normal PTT

Lupus Anticoagulant

Other Tests

- Only ~50% patients with LA have ↑PTT
- Other coagulation tests sometimes used
  - Dilute Russell viper venom time
  - Kaolin clotting time
- Time to clot will be prolonged if LA present
- Time to clot will not correct with mixing study

Antiphospholipid Antibodies

Testing



Antiphospholipid Syndrome

- Syndrome = one laboratory plus one clinical criteria
- Lab criteria (2 positive results >12 weeks apart):
  - Lupus anticoagulant
  - Anti-cardiolipin
  - Anti-β2-glycoprotein
- Clinical criteria:
  - Arterial or venous thrombosis
  - Fetal death after 10 weeks of normal fetus
  - >=3 consecutive fetal losses before 10 weeks

Hypercoagulable Workup

- Panel of tests for hypercoagulable states
- Sometimes performed in:
  - Unprovoked DVT/PE
  - Stroke/MI at an early age
- Controversial
  - Expensive
  - Rarely changes management
  - Few data on management of identified states
  - Risk of bleeding with indefinite anticoagulation
- Some tests altered by thrombus or blood thinners

Hypercoagulable Workup

- Antithrombin level
- Protein C and S levels
- Factor V Leiden gene mutation
- Prothrombin gene mutation
- Antiphospholipid antibodies
- Cancer screening

Coagulopathies

Jason Ryan, MD, MPH

Bleeding Disorders

- Abnormal coagulation cascade
  - Hemophilia, Vitamin K deficiency
- Abnormal platelets
  - Bernard-Soulier, Glanzmann's Thrombasthenia
  - ITP, TTP
  - Uremia
- Mixed Disorders
  - Von Willebrand Disease, DIC, Liver disease

Bleeding Time

- Test of **platelet function**
- Small cut to patient's arm
- Filter paper applied/removed until bleeding stops
- Rarely done in modern era

PTT

Activated Partial Thromboplastin Time



(PTT)

Add Plasma to (-) charge substance (silica)

Time to form clot

Normal ~30s

PT

Prothrombin Time



Prothrombin Time (PT)
Add Plasma to TF
Time to form clot
Normal ~10s

$$\text{INR} = \frac{\text{Patient PT}}{\text{Control PT}}$$

Normal = 1
Therapeutic = 2-3

Thrombin Time



Type of Bleeding

- Abnormal **platelets**
  - Mucosal bleeding, **skin** bleeding, petechiae
- Abnormal **coagulation factors**
  - **Joint** bleeding, deep tissue bleeding



Hektor/Wikipedia

Hemophilias

- X-linked recessive diseases
- Gene mutations: Run in families; also occur de novo
- **Hemophilia A**: Deficiency of factor VIII
- **Hemophilia B**: Deficiency of factor IX
  - Also called Christmas disease

Alexei Nikolaevich



Hemophilias

- Present with spontaneous or easy bruising
- Recurrent **joint bleeds** is common presentation
- Screening: **PTT will be prolonged**
  - Factors VIII, IX both part of intrinsic pathway
- **PT, bleeding time, platelet count all normal**

Coagulation Cascade

Hemophilias

Treatment

- Replacement factor VIII and IX



Biggishben~commonswiki

Hemophilias

Treatment

- Desmopressin (dDAVP)
  - Used in mild **hemophilia A**
  - Analogue of vasopressin (ADH) with no pressor activity
  - **Increases vWF and factor VIII levels**
  - Releases VIII from **Weibel-Palade bodies**(endothelial cells)

Desmopressin

- Also has vasodilating properties
- Key side effects: **flushing, headache**
- Other uses:
  - von Willebrand disease
  - Central diabetes insipidus (mimics ADH)
  - Bedwetting (decreases urine volume)

Hemophilias

Treatment

- **Aminocaproic acid**
  - Antifibrinolytic drug
  - Inhibits plasminogen activation → plasmin
  - Less breakdown of formed clots

Cryoprecipitate

"Cryo"

- Obsolete therapy for hemophilia A
- Precipitate that forms when FFP is thawed
- Separated from plasma by centrifugation
- Contains **factor VIII, fibrinogen**
- Also factor XIII and von Willebrand factor (VWF)
- Often used as **source of fibrinogen**
  - DIC
  - Massive trauma with blood transfusions

Coagulation Factor Inhibitors

- Antibodies
- Inhibit activity or increase clearance of clotting factor
- Inhibitors of **factor VIII** most common
- Often occur in association with:
  - Malignancy
  - Post-partum
  - Autoimmune disorders
- Can be treated with **prednisone**



Martin Brändli /Wikipedia

Coagulation Factor Inhibitors

- Can present similar to hemophilia
  - Deficient activity of VIII → bleeding
  - Prolonged PTT
- **Mixing study** will differentiate from hemophilia A

Mixing Study

- Clotting factors ~50% normal → normal PT/PTT



Mixing Study

- Clotting factors ~50% normal → normal PT/PTT



Vitamin K Deficiency

- Results in **bleeding**
- Deficiency of vitamin K-dependent factors
  - II, VII, IX, X
- Key lab findings:
  - **Elevated PT/INR**
  - Can see elevated PTT (less sensitive)
  - Normal bleeding time

Vitamin K Deficiency

- Dietary deficiency rare
- GI bacteria produce sufficient quantities
- Common causes:
  - Warfarin
  - **Antibiotics** (deplete GI bacteria)
  - Newborns (sterile GI tract)
  - Malabsorption (Vitamin K is fat soluble)

Blood Transfusion

- Large volume transfusions → dilution clotting factors
- Packed RBCs: devoid of plasma/platelets
  - Removed after collection
- Saline or IVF: No clotting factors
- Treated with **fresh frozen plasma**

"Blausen gallery 2014".
Wikiversity Journal of Medicine.

Liver Disease

- Loss of **clotting factors**
  - Advanced liver disease → ↓ clotting factor synthesis
  - Most clotting factors produced in liver
  - Exception: Factor VIII produced in endothelial cells
  - **PT more sensitive** to liver disease (vitamin K)
- **Thrombocytopenia** also common
  - Decreased hepatic synthesis of **thrombopoietin**
  - Platelet sequestration in spleen from portal hypertension

Platelet Disorders

Jason Ryan, MD, MPH

Bleeding Disorders

- Abnormal coagulation
  - Hemophilia, Vitamin K deficiency
- Abnormal platelets
  - Bernard-Soulier
  - Glanzmann's Thrombasthenia
  - ITP, TTP
  - Uremia
- Mixed Disorders
  - Von Willebrand Disease, DIC

Type of Bleeding

- Abnormal **platelets**
  - Mucosal bleeding, **skin** bleeding, petechiae
- Abnormal **coagulation factors**
  - **Joint** bleeding, deep tissue bleeding



Hektor/Wikipedia

Bleeding Time

- Test of **platelet function**
- Small cut to patient's arm
- Filter paper applied/removed until bleeding stops
- Rarely done in modern era

Inherited Platelet Disorders



Glanzmann's Thrombasthenia

- Autosomal recessive disorder
- Functional **deficiency of GPIIb/IIIa receptors**
- Bleeding, often epistaxis
- Key diagnostic finding:
  - Prolonged bleeding time
  - Blood smear: **Isolated platelets** (no clumping)
  - **Absent platelet aggregation** in response to stimuli
  - Abnormal platelet aggregometry
  - Platelets mixed with ADP, arachidonic acid

Bernard-Soulier Syndrome

- Autosomal recessive disorder
- **Deficiency of GPIb platelet receptors**
- Platelets cannot bind vWF
- Also results in **large platelets**
- Bleeding, often epistaxis or menorrhagia
- Key lab findings:
  - Prolonged bleeding time
  - **Thrombocytopenia**
  - Large platelets on blood smear

Giant Platelets

- Can be seen in association with thrombocytopenia
- Caused by rare inherited disorders
  - Bernard-Soulier, others



Bobjgalindo/Wikipedia

Wiskott-Aldrich Syndrome

- Immunodeficiency syndrome of infants
- X linked disorder of WAS gene (WAS protein)
  - Necessary for T-cell **cytoskeleton** maintenance
- Triad:
  - **Immune dysfunction**
  - **↓ platelets**
  - **Eczema**

ITP

Idiopathic thrombocytopenic purpura

- Disorder of decreased platelet survival
- Commonly caused by **anti-GPIIB/IIIA antibodies**
- Consumption **splenic macrophages**



ITP

Idiopathic thrombocytopenic purpura

- Diagnosis of exclusion
  - Rule out other causes of bone marrow suppression
- Treatment:
  - Steroids
  - IVIG (blocks Fc receptors in macrophages)
  - Splenectomy

TTP

Thrombotic thrombocytopenic purpura

- Disorder of **small vessel thrombus** formation
- Consumes platelets → thrombocytopenia
- ↓ activity of vWF cleaving protease **ADAMTS13**

Von Willebrand Factor

Multimers

- vWF synthesized a protein **monomer**
  - Occurs in endothelial cells and megakaryocytes
- Monomers link in endoplasmic reticulum → dimers
- vWF dimers move to Golgi → multimers

Von Willebrand Factor

Multimers

- Large multimers stored:
  - Endothelial Weibel–Palade bodies
  - Platelet α-granules
- Large multimers can obstruct blood flow
- **ADAMTS13** prevents obstruction
  - Enzyme (metalloprotease)
  - **Breaks down multimers of vWF**
  - Prevents thrombotic occlusion

ADAMTS13



TTP

Cause

- Severe ADAMTS13 deficiency
  - Usually <10% normal activity
- Usual cause: **acquired autoantibody** to ADAMTS13
- Result: vWF multimers in areas of high shear stress
- Obstruction small vessels



MAHA

Microangiopathic hemolytic anemia

- Hemolytic anemia (↑LDH, ↓ haptoglobin)
- Caused by **shearing of RBCs** as they pass through thrombi in small vessels
- Blood smear: schistocytes
- Seen in:
  - TTP
  - HUS
  - DIC



Paulo Henrique Orlandi Mourao

TTP

Thrombotic thrombocytopenic purpura

- Fever
  - Inflammation from small vessel occlusion and tissue damage
- **Neurological symptoms**
  - Headache, confusion, seizures
- Renal failure
- **Petechiae** and bleeding

TTP

Thrombotic thrombocytopenic purpura

- Lab tests:
  - Hemolytic anemia
  - Thrombocytopenia
  - Schistocytes on blood smear
- PT/PTT should be normal
  - Contrast with DIC
- May see elevated d-dimer

TTP

Treatment

- **Plasma exchange**: removes antibodies
- **Platelet counts** monitored to determine efficacy

Mr Vacchi /Wikipedia

Hemolytic Uremic Syndrome

HUS

- Many similarities with TTP
- Also caused by platelet-rich thrombi in small vessels
- MAHA, thrombocytopenia, acute kidney injury
  - Usually no fever or CNS symptoms
  - Renal thrombi → kidney injury
- Commonly seen in **children**
- Commonly follow GI infection E. Coli O157:H7
  - **Shiga-like toxin** causes microthrombi

DIC

Disseminated Intravascular Coagulation

- Widespread activation of clotting cascade
- Diffuse thrombi (platelets/fibrin) → ischemia
- Consumption of clotting factors and platelets
- Destruction of red blood cells → anemia

DIC

Disseminated Intravascular Coagulation

- Occurs secondary to another process
- Obstetrical emergencies
  - Amniotic fluid contains **tissue factor**
  - DIC seen in conjunction with amniotic fluid embolism
- Sepsis
  - **Endotoxin** –> activates coagulation cascade
  - Cytokines

DIC

Disseminated Intravascular Coagulation

- Leukemia
  - Especially acute promyelocytic leukemia (APML)
  - Cancer: well-described hypercoagulable state
  - Excess coagulation: DIC
- Rattlesnake bites
  - **Thrombin-like glycoproteins** within venom
  - Diffuse activation of clotting

Andy king50/Wikipedia

DIC

Disseminated Intravascular Coagulation

- **Elevated PT/PTT/Thrombin time**
  - Consumption of factors
- **Low platelets**
  - Consumption of platelets
- **Low fibrinogen** (consumption)
- Microangiopathic hemolytic anemia
  - Low RBC (**anemia**)
  - Schistocytes on blood smear
- Elevated **D-dimer**

DIC

Disseminated Intravascular Coagulation

- Treatment: underlying disorder
- Fresh frozen plasma: replace clotting factors
- RBCs, platelets
- Cryoprecipitate (for **low fibrinogen**)

ITP, TTP, HUS, DIC

	ITP	TTP	HUS	DIC
↓ Platelets	+	+	+	+
Hemolytic Anemia	--	+	+	+
↑PT/PTT	--	--	--	+



Uremia

- Renal dysfunction → bleeding
- Poor aggregation and adhesion of platelets
- Caused by uremic toxins in plasma
  - Uremic platelets work normally in normal serum
- Prolonged **bleeding time**
- Normal platelet count
- Normal coagulation testing

Thrombocytopenia

- Decreased production of platelets
  - Chemotherapy, leukemia
  - Sepsis (bone marrow suppression)
- Platelet sequestration
  - Splenomegaly
  - Portal hypertension
- Platelet destruction
  - ITP, TTP

Thrombocytopenia

- Normal platelet count: 150,000/ml to 400,000/ml
- Bleeding occurs when **<10,000**
- Treatment: Platelet transfusions

Von Willebrand Disease

- Deficient function of von Willebrand Factor
  - Large glycoprotein
  - Synthesized by **endothelial cells** and **megakaryocytes**
  - Present in platelets
- Two key roles in hemostasis
  - **Carrier of factor VIII** (intrinsic coagulation pathway)
  - **Binds platelets** to endothelium and other platelets

Von Willebrand Disease

- **Most common inherited bleeding disorder**
  - Affects up to 1 percent of population
- Gene mutations → ↓ level or function of vWF
  - Most cases autosomal dominant (males=females)

Von Willebrand Disease

- Usually mild, non-life-threatening bleeding
- Easy bruising
- Skin bleeding
- Prolonged bleeding from mucosal surfaces
  - Severe nosebleeds
  - **Menorrhagia**

Von Willebrand Disease

Diagnosis

- Normal platelet count
- Normal PT
- **Increased PTT** (depending on severity)
  - Usually no joint/deep tissue bleeding
- **Increased bleeding time**

Von Willebrand Disease

Diagnosis

- **Ristocetin cofactor activity assay**
- Ristocetin: antibiotic off market due to ↓platelets
- Binds vWF and platelet glycoprotein Ib
- Causes platelet aggregation if vWF present



Von Willebrand Disease

Treatment

- vWF concentrate
- **Desmopressin**
  - **Increases vWF and factor VIII levels**
  - Releases vWF from endothelial cells
- **Aminocaproic acid**
  - Antifibrinolytic drug
  - Inhibits plasminogen activation → plasmin
  - Less breakdown of formed clots

Heyde's Syndrome

- **GI bleeding** associated with **aortic stenosis**
- Angiodysplasia
  - Vascular malformations of GI tract
  - Prone to bleeding
  - Commonly occur in aortic stenosis patients
- Deficiency of **von Willebrand factor**
  - High shearing force caused by aortic stenosis
  - Uncoiling of vWF multimers
  - Exposes cleavage site for **ADAMTS13**
- Improves after aortic valve surgery

Antiplatelets

Jason Ryan, MD, MPH

Thrombus Formation



Thrombus Formation



Antiplatelets



Thromboxane (from arachidonic acid)
Adenosine diphosphate (ADP)
↓cAMP (via ADP)

Aspirin



Aspirin

- Inhibits COX-1 and COX-2
  - Both found in platelets
- Blunts conversion of AA to TXA2
- **↓ platelet activity**
- Also inhibits production of prostaglandins

Eicosanoids



Eicosanoids

Mediator	Effects
PGE_2	Redness (vasodilation) Edema (permeability) Fever (hypothalamus) Pain (nerves) Renal vasodilation (afferent)
PGE_2/PGI_2	Protect GI mucosa
TXA_2	Platelet activation

Ricciotti E, FitzGerald G; **Prostaglandins and Inflammation**
Arterioscler Thromb Vasc Biol. 2011 May; 31(5): 986–1000.

NSAIDs

Ibuprofen, naproxen, indomethacin, ketorolac, diclofenac

- Aspirin is technically NSAID
- NSAIDS **reversibly** inhibit COX-1 and COX-2
- Aspirin **irreversibly** inhibits COX-1 and COX-2
- Decreases activity for lifetime of platelet (7-10days)
- All NSAIDs may cause bleeding
- All NSAIDs reduce pain, inflammation via ↓ PGs

Aspirin

Common antiplatelet uses

- **Coronary disease**
  - Acute myocardial infarction/unstable angina
  - Secondary prevention
- **Stroke**
  - Acute ischemic stroke
  - Secondary prevention

Aspirin

Adverse Effects

- **Bleeding**
- Gastritis/Ulcers
  - COX important for maintenance of **GI mucosa**
- **Tinnitus**
  - Caused by salicylate (aspirin metabolite: salicylic acid)
  - Alters cochlear nerve function
  - Rare: Usually occurs with very high doses
  - Resolves with discontinuation

Aspirin

Adverse Effects

- Reye's syndrome
  - **Liver failure** and **encephalopathy**
  - Associated with aspirin use in children
  - Aspirin not generally used in kids (exception: Kawasaki)

Thienopyridines

Ticlopidine, clopidogrel, prasugrel



Ticlopidine

- **Irreversible** $P2Y_{12}$ receptor blockers
- Block effects of ADP on platelets
- Used in aspirin allergy
- Added to aspirin for prevention of MI, Stroke
- Major adverse effect is **bleeding**
- Rare, dangerous adverse effect: **TTP**

TTP

Thrombotic Thrombocytopenic Purpura

- Associated with thienopyridine drugs
- Severe thrombocytopenia
- Microangiopathic hemolytic anemia
- Neurologic abnormalities
- Deficient activity of ADAMTS13
- Antibodies to ADAMTS13

Ticagrelor

- Cyclo-pentyl-triazolo-pyrimidine (CPTP)
  - NOT a thienopyridine
- **Reversible** antagonist to $P2Y_{12}$ receptor
- Unique side effect: **Dyspnea**
  - Mechanism unclear

Phosphodiesterase Inhibitors

PDE Inhibitors

- Inhibit phosphodiesterase III in platelets
- PDE breaks down cAMP
- ↑ cAMP → ↓ platelet activation
- Two drugs in class: **dipyridamole, cilostazol**

Dipyridamole

- PDEIII inhibitor
- Inhibits platelet activation
- Also blocks adenosine uptake by cells
  - Adenosine = vasodilator
  - **Raises adenosine levels → vasodilation**
- Used with aspirin for **stroke prevention** (antiplatelet)
- Used in chemical **cardiac stress testing** (vasodilator)

Cilostazol

- PDEIII inhibitor
- Inhibits platelet activation
- Also raises cAMP in vascular smooth muscle
- Vasodilator
- Rarely used for anti-platelet effects
- Used in **peripheral arterial disease**

Phosphodiesterase Inhibitors

Dipyridamole, Cilostazol

- Many side effects related to vasodilation
  - **Headache**
  - **Flushing**
  - **Hypotension**

IIB/IIIA Receptor Blockers

- **Abciximab, eptifibatide, tirofiban**
- Bind and block IIB/IIIA receptors
- Abciximab: Fab fragment of antibody to IIB/IIIA
- IV drugs used in acute coronary syndromes/stenting



Eptifibatide



Tirofiban

IIB/IIIA Receptor Blockers

- Main adverse effect is bleeding
- Can cause **thrombocytopenia**
  - May occur within hours of administration
  - Mechanism poorly understood
  - **Must monitor platelet count** after administration

Antiplatelet Drugs



Anticoagulant Drugs

Jason Ryan, MD, MPH

Thrombus Disorders

Disease	→	Thrombus Location
• Atrial Fibrillation		• Left atrial appendage
• Myocardial Infarction		• Coronary artery
• DVT/PE		• Deep vein/pulm artery
• Stroke		• CNS circulation
• Critical Limb Ischemia		• Peripheral circulation

Antithrombotic Drugs

- Acute therapy: Help eliminate clot already formed
- Prevention: Lower risk of clot in high risk patients

Thrombus Formation



Blood thinners



Bleeding

- Thrombus formation very beneficial
- Prevents/stops bleeding
- **BLEEDING:** common side effect
- Can occur with all antithrombotic/antiplatelet drugs

Clotting versus Bleeding

Myocardial Infarction
Pulmonary Embolism
Deep Vein Thrombosis
Stroke



GI Bleeding
CNS Bleeding
Bruising

Coagulation Cascade



PTT

Activated Partial Thromboplastin Time



(PTT)

Add Plasma to (-) charge substance (silica)

Time to form clot

Normal ~30s

PT

Prothrombin Time



Prothrombin Time (PT)
Add Plasma to TF
Time to form clot
Normal ~10s

$$\text{INR} = \frac{\text{Patient PT}}{\text{Control PT}}$$

Normal = 1
Therapeutic = 2-3

Thrombin Time



Heparin

- Polymer (glycosaminoglycan)
- Occurs naturally (found in **mast cells**)
- Molecules with varying chain lengths
- Used in two forms:
  - **Unfractionated**: widely varying polymer chain lengths
  - **Low molecular weight**: Smaller polymers only



Unfractionated Heparin



Unfractionated Heparin (UFH)

- Given IV or SQ → acute onset
- **Increases PTT**
  - Effects many components of intrinsic pathway
  - HeparIN = INtrinsic (PTT)
- Will also increase thrombin time
- Can increase PT at high dosages
- Lots of binding to plasma proteins, cells
  - Highly variable response from patient to patient
  - **Dose must be adjusted** to reach goal PTT

Protamine

- Reversal agent for unfractionated heparin
  - Less effective with LMWH
- Binds heparin → neutralizes drug
- Used in heparin overdose
- Used in cardiac surgery
  - High dose heparin administered for heart-lung bypass
  - Quick reversal at completion of case

Unfractionated Heparin (UFH)

- Uses:
  - Acute management: DVT/PE, MI, Stroke
  - Prophylaxis for DVT in hospitalized patients (SQ)

Unfractionated Heparin (UFH)

- Side Effects
  - Mainly bleeding and thrombocytopenia
  - Osteoporosis (long term use)
  - Elevated AST/ALT (mild)

Heparin and Thrombocytopenia

- Many patients → mild (10-20%) ↓ platelets
  - "Non-immune" thrombocytopenia
  - Direct suppressive effect platelet production
- Heparin-induced thrombocytopenia (HIT)
  - Immune-mediated reaction
  - Immune complexes bind **platelet factor 4-heparin**
  - **Type II hypersensitivity reaction**



HIT

Heparin-induced thrombocytopenia

- 5-10 days after exposure to heparin
- Abrupt fall in platelets (>50%)
- **Arterial/vein thrombosis**
- Rare: 0.2 – 5% Heparin patients
- Patients with HIT must use alternative drugs
  - Lepirudin, Bivalirudin (direct thrombin inhibitors)

HIT

Heparin-induced thrombocytopenia

- Presumptive diagnosis:
  - Significant drop in platelet count
  - Thrombosis formation
- Definitive diagnosis: HIT antibody testing
  - Autoantibodies to platelet factor 4 complexed with heparin

Low Molecular Weight Heparin

Enoxaparin



Low Molecular Weight Heparin

Enoxaparin



Low Molecular Weight Heparin

Enoxaparin

- Dose based on weight – no titrating
  - Reduced binding to plasma proteins and cells
- Given SQ
- Lower incidence of HIT (but may still cause!)

Low Molecular Weight Heparin

Enoxaparin

- Will not affect thrombin time (like UF heparin)
- PTT not sensitive to LMWH-induced changes
  - Unlike UF heparin, only factor X effected



Low Molecular Weight Heparin

Enoxaparin

- If monitoring required, must check **anti Xa levels**
  - Limited/insensitive affect on PTT
  - Standard dose based on weight
  - Usually no monitoring used
  - Exceptions: Obesity and renal failure

Anti-Xa Level



Factor Xa Inhibitors

Indirect inhibitors (ATIII)
Unfractionated Heparin
LMWH



Factor Xa Inhibitors

- Rivaroxaban, Apixaban
- Used in atrial fibrillation as alternatives to warfarin
  - Do not require monitoring of PT/INR
  - Standard dosing
- Can increase PT and PTT (Xa in both pathways)
- Will not affect thrombin time

Direct Thrombin Inhibitors



Direct Thrombin Inhibitors

Uses

- Can prolong **PT, PTT, and thrombin time**
- Thrombin activity common to all tests
- Only **UF heparin and DTIs** prolong thrombin time
  - Requires an inhibitor of thrombin function
  - UF Heparin: ATIII
  - DTIs: Direct drug effect

Direct Thrombin Inhibitors

Uses

- Patients with HIT
  - Hirudin, lepirudin, bivalirudin, desirudin, argatroban
  - Stop heparin, start DTI
  - PTT often monitored
- Acute coronary syndromes, coronary interventions
  - Bivalirudin
- Atrial fibrillation
  - Dabigatran (oral)
  - Standard dosing: does not require PT/INR monitoring

Warfarin

- Vitamin K Factors: II, VII, IX, and X
- Warfarin: **Antagonist to vitamin K**
- ↓ levels of all vitamin K dependent factors

Vitamin K

- Forms **γ-carboxyglutamate (Gla) residues**



Clotting Factor Precursor

Activated Clotting Factor

Vitamin K

- Found in **green, leafy vegetables** (K1 form)
  - Cabbage, kale, spinach
  - Also egg yolk, liver
- Also synthesized by **GI bacteria** (K2 form)

Warfarin

Vitamin K Antagonist



Clotting Factor Precursor

Activated Clotting Factor

Warfarin

- Takes days to achieve its effects
  - Time required for clotting factor levels to fall
- Dose adjusted to reach target **PT/INR**
  - Drugs effect varies with diet (vitamin K)
  - Antibiotics may ↓ GI bacteria → ↓ vitamin K→ ↑ INR
  - Some drugs interfere with metabolism

Vitamin K Dependent Factors



Vitamin K Dependent Factors

- **Factor VII has shortest half life**
  - First level to fall after Warfarin administration
- **Only PT captures factor VII activity**
- PTT less sensitive to Warfarin
- Thrombin time normal

Protein	Half-life (hours)
Factor VII	4-6
Protein C	8-10
Factor X	24-40
Protein S	40-60
Prothrombin (II)	60 - 72

Warfarin

Prothrombotic Effects

- Protein C: anti-clotting factor with **short half-life**
- Also **vitamin K dependent**
- Initial warfarin Rx → protein C deficient
  - This is pro-thrombotic
  - Brief…eventually other factors fall→ antithrombotic

Protein	Half-life (hours)
Factor VII	4 - 6
Protein C	8 - 10
Factor X	24 - 40
Protein S	40 - 60
Prothrombin (II)	60 - 72

Warfarin

Prothrombotic Effects

- Should you start another drug (heparin) anytime you start warfarin?
  - Yes, but this is usually not an issue
  - For clot disorders (DVT/PE) heparin used for acute onset
  - Heparin → anticoagulation during initial warfarin therapy
- One exception: Atrial fibrillation
  - No active clot; just risk of clot
  - Often start warfarin without heparin
  - Brief increase in risk of clot is very low

Warfarin

Adverse Effects

- **Crosses placenta**
  - Avoided in pregnancy
  - Fetal warfarin syndrome: abnormal fetal development
  - Unfractionated heparin often used (does not cross)
- Side Effects:
  - Mainly bleeding
  - Skin necrosis

Warfarin Skin Necrosis

- Rare complication of therapy
- Occurs in patients with **protein C deficiency**
- Can also occur with very high dosages
- Initial exposure to warfarin → ↓ protein C
- Result: **thrombosis of skin tissue**
- Large dark, purple skin lesions

Warfarin

Uses

- Stroke prevention atrial fibrillation
- Mechanical heart valves
- DVT/PE

Chronic Oral Anticoagulation

- Several Indications
  - Atrial Fibrillation
  - Mechanical heart valve
  - Prior DVT or PE
- Prior Standard: Warfarin
  - Oral drug, Low Cost
  - Downside: Requires INR checks (monthly blood draw)

Novel Oral Anticoagulants (NOACs)

Alternatives to Warfarin

- Factor Xa inhibitors
  - #1: Rivaroxaban
  - #2: Apixaban
- Direct Thrombin inhibitors
  - #3: Dabigatran
- Upside: No INR checks…consistent dose
- Downsides
  - Cost $$
  - Reversal agents - Idarucizumab

Thrombolysis



Powerful, "clot busters"
Used in acute MI, stroke
MAJOR bleeding risk

Reversal of drugs

- **Fresh Frozen Plasma (FFP)**
  - Plasma after removal of RBC, WBC, and Plt
  - Frozen for storage
  - Once thawed, must be used within 24hrs
  - Clotting factors degrade
  - Corrects deficiencies of any clotting factor
  - PT/PTT will normalize after infusion

Reversal of drugs

- Vitamin K
  - Reverses warfarin
  - Used with ↑ INR in absence of serious bleeding
  - Given PO or IV
  - IV can cause anaphylaxis
- INR 3-5: Hold warfarin
- INR 5-9: Hold warfarin, Oral vitamin K
- INR >9: Consider IV vitamin K, FFP

Severe bleeding + ↑INR = administer FFP

Hemolysis Basics

Jason Ryan, MD, MPH

Hemolysis

- Destruction of red blood cells
- Causes a **normocytic anemia**



Normocytic Anemias



Hemolysis

Extrinsic versus Intrinsic

- Extrinsic cause
  - Cause is extrinsic to the red cell
  - **Antibodies**
  - Mechanical trauma (narrow vessels)
  - RBC infection
- Intrinsic cause
  - Cause is intrinsic to red blood cells
  - Failure of membrane, hemoglobin, or enzymes
  - Membrane: Hereditary spherocytosis
  - Enzyme: G6PD deficiency
  - Hemoglobin: Sickle cell anemia (Abnormal Hgb)

Normocytic Anemias



Hemolysis

Consequences

- Normocytic anemia
- **Elevated plasma LDH**
  - Lactate dehydrogenase
  - Glycolysis enzyme
  - Converts pyruvate → lactate
  - Spills out of RBCs



Reticulocytes

- Immature red blood cells
- Usually about 1-2% of RBCs in peripheral blood
- Increased reticulocyte count: Hallmark of hemolysis

Hemolysis

↓

↑ EPO

↓

↑ Reticulocyte

Reticulocyte Count

- ↑ reticulocytes: normal marrow response to anemia
- Key blood test in **normocytic anemias**
- Normocytic anemia: ↓ production or ↑ destruction
- Reticulocyte count **differentiates between causes**
  - Low retic count: Underproduction
  - High retic count: Increased destruction (hemolysis)

Reticulocyte Count

- Normal: 1 to 2 %
- Anemia: 4-5%
- Must be **corrected** for degree of anemia
- If <2% → **inadequate bone marrow response**

Hct 45 (normal)
Retic 1% (normal) ⟶ Hct 11
Retic 8%

Corrected RC = 8% * (11/45) = 2%

Reticulocyte Production Index

- Normal reticulocytes circulate ~1day
- In anemia → premature release of reticulocytes
- **Can live longer** → circulate longer
- RPI corrects for longer life of reticulocytes in anemia
- RPI < 2% seen with bone marrow failure

$$\text{RPI} = \frac{\text{Corrected Retic \%}}{\text{Maturation Time}}$$

Hgb	MT
15	1
12	1.5
8	2
5	2.5

Hemolysis

Consequences

- **Elevated unconjugated (indirect) bilirubin**
- Not water soluble
- Bound to albumin in plasma



Heme

Bilirubin

Jaundice



Gallstones

- ↑ risk in hemolysis
- Pigment stones
  - Contain bilirubin
  - Less common type of gallstone (more common: cholesterol)

Emmanuelm/Wikipedia

Hemolysis

Intravascular versus Extravascular

- **Intravascular** hemolysis
  - Occurs inside blood vessels
- **Extravascular** hemolysis
  - Occurs in liver and spleen
- Both cause normocytic anemia and ↑ retic count

Extravascular Hemolysis

- **Liver**
  - Receives large portion cardiac output
  - Can remove severely damaged RBCs
- **Spleen**
  - Destroys poorly deformable RBCs
  - **Cords of Billroth**: Vascular channels that end blindly
  - Found in **red pulp** of spleen
  - RBCs must deform to pass through slits in walls of cords
  - Old ("senescent") or damaged RBCs remain in the cords
  - Phagocytosed by the macrophages
  - Hemolysis disorders → ↑ splenic removal of RBCs

Spleen



Intravascular Hemolysis

- Destruction of RBCs inside blood vessels
  - Outside of spleen
- Mechanical trauma
  - Narrowed vessels
  - Small vessels: thrombus ("microangiopathic")
  - Large vessels: mechanical heart valves

Haptoglobin

- Plasma protein
- **Binds free hemoglobin**
- Haptoglobin-hemoglobin complex removed by **liver**
- **↓ serum haptoglobin with hemolyisis**

Haptoglobin

- Intravascular: Hgb released directly into plasma
  - Haptoglobin **very low or undetectable**
- Extravascular: Some Hgb released from spleen
  - Haptoglobin can be **low or normal**
- Classically taught as low in intravascular only
- Studies show can be low in both types

Kormoczi G. **Influence of clinical factors on the haemolysis marker haptoglobin**. Eur J Clin Invest 2006 Mar;36(3)

Haptoglobin

- Produced by the liver
- **Acute phase reactant**
- Increased levels with inflammation
- Decreased levels in cirrhosis

Hemolyisis

Urine findings

- No bilirubin
  - Unconjugated bilirubin not water soluble
  - Cannot pass into urine

Hemolyisis

Urine findings

- Intravascular hemolyisis
  - Haptoglobin saturation → **free excess hemoglobin**
  - "Hemoglobinemia"
  - Filtered in kidneys → **hemoglobinuria**
  - Some reabsorbed in proximal tubules
  - Iron converted into ferritin → **hemosiderin** in tubular cells
  - Tubular cells slough into urine
  - Prussian blue stain on sediment shows hemosiderinuria

Hemolyisis

Urine findings

- Hemoglobin part of urine dipstick
- Hgb may turn urine red/brown
  - Also occurs in rhabdomyolysis
  - Myoglobin from muscle damage
- **No red cells plus + Hgb**



James Heilman, MD -

Hemolysis

Classic Findings

- Normocytic anemia
- ↑ LDH
- ↑ Indirect bilirubin
- ↑ Reticulocyte count
- ↓ Haptoglobin (lower in intravascular)
- Urine Hgb and hemosiderin (intravascular)

Parvovirus B19

- DNA virus
- Replicates in **RBC progenitor cells**
- ↓erythropoiesis

Parvovirus B19

- Healthy patients:
  - RBC production returns 10 to 14 days; mild/no anemia
- Hemolysis patients
  - Increased RBC turnover
  - Lack of erythropoiesis leads to severe anemia
  - Pallor, weakness, and lethargy

Parvovirus B19

- "Aplastic Crisis" in patients with chronic hemolysis
  - Sickle cell anemia
  - Hereditary spherocytosis
  - Beta thalassemia major
- Classic scenario:
  - Worsening anemia with **LOW reticulocyte count**

Back and Abdominal Pain

- Seen in some hemolytic syndromes
- Abdominal pain can be caused by splenomegaly
- May be due to smooth muscle spasm
- **Nitric oxide**: scavenged by free hemoglobin
- Common in some hemolytic disorders
  - Paroxysmal nocturnal hemoglobinuria
  - G6PD deficiency

Extrinsic Hemolysis

Jason Ryan, MD, MPH

Normocytic Anemias



Extrinsic Hemolysis

- Antibodies
- Trauma/shearing
- Red cell infections

AIHA

Autoimmune Hemolytic Anemia

- Red cell destruction from **autoantibodies**
- Results in extravascular hemolysis
- Red cell membrane removed in pieces by spleen
- Can be “warm” or “cold”

Warm AIHA

- Most common type of AIHA
- Antibodies bind at **body temp 37°C** ("warm")
- **IgG antibodies** against RBC surface antigens

Warm AIHA

Signs and symptoms

- **Anemia**
  - Fatigue
  - Pallor (pale skin)
  - Dyspnea
  - Tachycardia
- **Extravascular hemolysis**
  - Jaundice
  - Splenomegaly

Warm AIHA

Diagnostic Findings

- **Spherocytes**
  - Smaller than normal RBCs
  - Spherical



Ed Uthman

Direct Antiglobulin Test

DAT or Coombs Test

- Test for red blood cell antibodies
- Patient RBCs plus **anti IgG** antiserum
- Positive if agglutination occurs
- Indicates patient's **RBCs covered with IgG**

Direct Antiglobulin Test

DAT or Coombs Test



Indirect Antiglobulin Test

Indirect Coombs

- Also a test for red blood cell antibodies
- Not generally used in warm/cold AIHA
- Tests for **antibodies in the serum**
- Patient's serum (not RBCs) tested
- Added to RBCs
- Indicates **antibodies to RBC components**

Indirect Antiglobulin Test

Indirect Coombs



Antiglobulin Tests

- Direct antiglobulin test
  - Test for **antibodies *bound* to RBCs**
  - Commonly used in **hemolytic anemias**
- Indirect antiglobulin test
  - Test for **antibodies in serum**
  - Will serum react with RBCs?

Warm AIHA

Associated Conditions

- Most cases idiopathic
- Associated with:
  - Lupus
  - Non-Hodgkin lymphoma
  - Chronic lymphocytic leukemia (CLL)

Methyldopa

α methyldopa

- **Antihypertensive drug of choice in pregnancy**
  - Agonists to CNS α2 receptors
  - Synapses believe too much sympathetic outflow
  - Decrease sympathetic tone in body
- **Associated with warm AIHA**

Øyvind Holmstad/Wikipedia

Methyldopa

α methyldopa

- Triggers production of RBC antibodies
  - Unclear mechanism
  - Drug may alter Rh antigens on red cells
  - **Red cells bind antibody in absence of drug**
- **Direct Coombs test: positive**

Penicillin

- High doses can lead to hemolytic anemia
- PCN binds to surface RBCs ("hapten")
  - Elicits immune response ***only when bound***
- **Antibodies against PCN bound to RBCs**
- **Direct Coombs test: positive**

Warm AIHA

Treatment

- **Glucocorticoids**
- Immunosuppressants
- **Splenectomy**

Cold AIHA

- Less common type of AIHA
- Antibodies bind at <30°C ("cold")
  - Occurs in **limbs**
  - Also **fingertips, toes, nose, ears**
- May present with painful fingers/toes
  - **Purple discoloration**
- Symptoms associated with cold exposure

Cold AIHA

Cold Agglutinin Disease

- Caused by IgM antibodies that agglutinate RBCs
- RBCs warmed in central organs → IgM lost
- Leaves bound C3 on RBCs
- **DAT positive only for C3**



Martin Brändli /Wikipedia

Direct Antiglobulin Test

DAT or Coombs Test



Cold AIHA

Cold Agglutinin Disease

- Usually causes **extravascular hemolyisis**
  - C3 coated RBCs removed by spleen
  - Often engulfed whole
  - Spherocytosis less common than in warm AIHA
- Intravascular hemolysis rarely occurs
  - Complement usually does not activate
  - RBCs: complement inhibitory molecules (CD55/CD59)
  - Complement must be significantly activated to lyse cells

Cold AIHA

Associated conditions

- Can be seen in chronic lymphocytic leukemia (CLL)
- Often occurs secondary to infection
  - **Mycoplasma pneumonia**
  - Epstein–Barr virus (**Infectious mononucleosis**)

Cold AIHA

Treatment

- Avoid cold (stay warm!)
- Immunosuppressants

Public Domain/Wikipedia

MAHA

Microangiopathic hemolytic anemia

- **Shearing of RBCs in small blood vessels**
- Thrombi in microvasculature → narrowing
- Blood smear: schistocytes
- Seen in:
  - TTP
  - HUS
  - DIC



Paulo Henrique Orlandi Mourao

Malignant Hypertension

- Associated with MAHA
- Endothelial injury → thrombus formation
- Improved with BP control

Public Domain

Mechanical Hemolysis

- **Shear forces** destroy RBCs in **large** blood vessels
- Seen in:
  - **Aortic stenosis**
  - **Mechanical heart valves**
  - Left ventricular assist devices
- Hemolytic anemia may occur
- Schistocytes can be seen on blood smear

Red Blood Cell Infections

- May cause hemolytic anemia
- Classic infectious agents: **Malaria, Babesia**

Babesia
Ring Forms



Malaria
Trophozoite Ring



CDC/Public Domain

Intrinsic Hemolysis

Jason Ryan, MD, MPH

Normocytic Anemias



PNH

Paroxysmal Nocturnal Hemoglobinuria

- RBC destruction via **complement system**
- Loss of protective proteins in RBC membrane
  - Decay Accelerating Factor (DAF/CD55)
  - MAC inhibitory protein (CD59)
- Predominantly **intravascular hemolysis**
- Some extravascular hemolysis
  - Macrophage destruction of RBCs opsonized with C3 fragments

PNH

Paroxysmal Nocturnal Hemoglobinuria

- **Acquired** genetic mutation in stem cell
  - Loss of **glycosylphosphatidylinositol (GPI) anchor**
  - Attaches proteins to cell surface
  - Lead to loss of DAF/CD59 on RBC cell membranes
- Platelets/WBCs may also have lysis

PNH

Paroxysmal Nocturnal Hemoglobinuria

- Classically causes sudden **hemolysis at night**
  - Slowing of respiratory rate with sleep
  - Also shallow breathing
  - Mild ↑CO2 → mild resp. acidosis → ↑ complement activity
- Fatigue, dyspnea
  - Anemia from hemolysis
  - May also lose iron in urine
  - **Iron-deficiency is common**

PNH

Paroxysmal Nocturnal Hemoglobinuria

- Abdominal pain (smooth muscle tension)
- Thrombosis
  - **Leading cause of death**
  - Usually venous clots
  - Unusual locations: portal, mesenteric, cerebral veins
- Some patients develop acute myeloid leukemia (AML)
  - Stem cell mutation progresses to acute leukemia
  - Lifetime risk: 5 percent or less

PNH

Paroxysmal Nocturnal Hemoglobinuria



PNH

Diagnosis

- Suspected with hemolysis, unexplained thrombosis
- Labs may show evidence of hemolysis
  - LDH, Low haptoglobin
  - Urine hemoglobin or hemosiderin
- Direct antibody testing (Coombs) will be negative
- **Flow cytometry** confirms diagnosis
  - Monoclonal antibodies to GPI-anchored proteins
  - Cells will be deficient in GPI-anchored proteins

Eculizumab

- **Anti-complement therapy**
- **Antibody** that binds to complement component C5
  - Prevents cleavage to C5a and C5b
- Blocks formation of membrane attack complex (MAC)
- Protects against intravascular hemolysis
- Does not protect against extravascular hemolysis
  - C3 fragments still bind RBCs → spleen
  - Treated patients may still have mild anemia
- Results in stable Hgb levels, **fewer transfusions**

Pyruvate Kinase Deficiency

- Deficiency of pyruvate kinase
- Key enzyme in **glycolysis**
- **RBCs** most effected
  - No mitochondria
  - Require PK for anaerobic metabolism
- **Membrane failure** → phagocytosis in spleen



Pyruvate Kinase Deficiency

- Autosomal recessive disorder
- Usually presents as **newborn**
- **Extravascular hemolysis**
- Splenomegaly
- Disease severity ranges based on enzyme activity

G6PD Deficiency

Glucose-6-Phosphate Dehydrogenase

- Key enzyme in **HMP shunt**
- HMP shunt necessary for generation of **NADPH**
- NADPH protects RBCs from **oxidative damage**

G6PD Deficiency

Glucose-6-Phosphate Dehydrogenase

- H_2O_2 toxic to RBCs
- H_2O_2 generation triggered by:
  - Infections
  - Drugs
  - Fava beans
- Need NADPH to degrade H_2O_2
- Absence of required NADPH → **hemolysis**

G6PD Deficiency

Glucose-6-Phosphate Dehydrogenase

- **X-linked** recessive disorder (males)
- Most common human enzyme disorder
- **Recurrent hemolysis** after exposure to trigger
  - Red cells become rigid
  - Consumed by splenic macrophages (**extravascular**)
  - Some lysis in blood vessels (intravascular)

Exposure to Trigger → **Hemolysis**

G6PD Deficiency

Triggers

- Infection: Macrophages generate free radicals
- Fava beans: Contain oxidants
- Drugs:
  - Antibiotics (**sulfa drugs**, dapsone, nitrofurantoin, INH)
  - **Anti-malarials** (primaquine, quinidine)
  - Aspirin, acetaminophen (rare)

G6PD Deficiency

Glucose-6-Phosphate Dehydrogenase

- High prevalence in **Africa,** Asia, the Mediterranean
  - May protect against malaria



Cappelllini, Fiorelli, Lancet 2008; 371: 64-74

G6PD Deficiency

Classic presentation

- Patient from Africa
- Jaundice, dark urine, anemia
- May have back pain (free Hgb)
- Onset after exposure to trigger

G6PD Deficiency

Glucose-6-Phosphate Dehydrogenase

- Classic findings: **Heinz bodies** and **bite cells**
- Heinz bodies: oxidized Hgb precipitated in RBCs
  - Seen with Heinz body stain ("Heinz body preparation")
- Bite cells: phagocytic removal by splenic macrophages



Heinz bodies



Bite cells

G6PD Deficiency

Diagnosis and Treatment

- Diagnosis:
  - Fluorescent spot test
  - Detects generation of NADPH from NADP
  - Add glucose-6-phosphate and NADP to red cells
  - Positive test if blood spot **fails to fluoresce** under UV light
- Must test outside of acute attack
  - Triggers → destruction of enzyme-poor cells
  - Remaining cells may have normal enzyme levels
- Treatment:
  - Avoidance of triggers

Hereditary Spherocytosis

- Hereditary disorder
  - Can be autosomal dominant or recessive
- Results in **spherocytes**
  - Slightly smaller than normal RBCs
  - Spherical shape
  - Lacks central pallor



Ed Uthman

Hereditary Spherocytosis

- Cytoskeleton abnormality
  - Abnormal **proteins that tie cytoskeleton to RBC membrane**
  - Common involves **spectrin**
  - Other proteins: ankyrin, band 3, band 4.2



Hereditary Spherocytosis

- O2 carrying function of spherocytes normal
- Disease from **chronic destruction in spleen**
  - Splenomegaly (growth of splenic macrophages)
  - Increased bilirubin
  - Jaundice
  - Bilirubin gallstones

Hereditary Spherocytosis

- **Progressive** loss of cell membrane
- Over time, more and more membrane lost
- Results in a **high RDW**



Hereditary Spherocytosis

- Volume does not change over time
- Results in a **high MCHC**
- MCV usually normal or low
  - Spherocytes: low MCV
  - Reticulocytes: high MCV



Normal



Spherocyte

Hereditary Spherocytosis

- Loss of membrane flexibility → more rigid cells
- High **resistance to blood flow** in small vessels

$$R = \frac{\Delta P}{Q} = \frac{8\,\eta\ (\text{viscosity})\ L\ (\text{length})}{\Pi\ r\ (\text{radius})^{4}}$$

Poiseuille's Law

Hereditary Spherocytosis

- Risk of aplastic crisis with **parvovirus B19 infection**
  - Patients dependent on marrow to replace hemolyzed cells
- Initial presentation may be a child with infection
  - Hemolysis compensated until B19 exposure
  - Spherocytosis seen on blood smear
  - Don’t confuse with G6PD

Hereditary Spherocytosis

Diagnosis

- **Osmotic fragility test**
- Spherocytes: susceptible to osmotic lysis
  - Poor ability to swell like normal RBCs
  - Will lyse in hypotonic solution
- Measure Hgb release in hypotonic solution
- Osmotic fragility will be ↑ if spherocytosis present

Hereditary Spherocytosis

- Treatment: **Splenectomy**
- Spherocytes will persist but hemolysis resolves
- Howell–Jolly bodies appear
  - Some RBCs leave marrow with nuclear remnants
  - Normally cleared by spleen
  - Presence in peripheral blood indicates splenic dysfunction
- Classic finding: spherocytes and Howell-Jolly bodies
  - Indicates patient post-splenectomy for spherocytosis

Howell-Jolly Bodies



Paulo Henrique Orlandi Mourao /Mikael Häggström

Microcytic Anemias

Jason Ryan, MD, MPH

Red Blood Cell Measurements

- RBC count
  - Part of CBC with white cell count and platelets
- Hemoglobin
  - Concentration in g/dl
- Hematocrit
  - Volume % of red cells



MesserWoland/Wikipedia

Rule of 3

- Hgb = 3 x Red Blood Cell Count
- Hct = 3 x Hgb

Normal Values

RBC = 5 million cells/ul

Hgb = 15g/dl

Hct = 45%

RBC Indices

- Measured by automated blood counters
- Measures of **mean** characteristics of RBCs
- Used in evaluation of anemias

RBC Indices

- **Mean corpuscular volume** (MCV)
  - Normal range: 80 to 100 femtoliters
- **Mean corpuscular hemoglobin** (MCH)
  - Amount (mass) of hemoglobin per red cell
  - Usually reported in picograms (per cell)
- **Mean corpuscular Hgb concentration** (MCHC)
  - Concentration of Hgb in red cells
  - Usually reported g/dL

Anemia Classification

- MCV commonly used to classify anemias

Microcytic MCV<80	Normocytic MCV 80-100	Macrocytic MCV>100
Iron deficiency	Iron deficiency	Folate/B12 deficiency
Anemia Chronic Disease	Anemia Chronic Disease	Orotic Aciduria
Thalassemia	Hemolysis	Liver disease
Lead poisoning	Aplastic anemia	Alcoholism
Sideroblastic Anemia	Kidney disease	Reticulocytosis

Microcytic Anemias

- Usually due to ↓ **hemoglobin** in red cells
- Usually associated with ↓ MCH and MCHC
- Low hemoglobin → hypochromic RBCs on smear



Hemoglobin

- **Globin chains**
  - Proteins
  - 4 chains in 2 pairs
- **Protoporphyrin**
- **Iron**
- Microcytic anemia
  - Loss of iron
  - Loss of globins (thalassemia)
  - Loss of heme (lead, sideroblastic)



Richard Wheeler and Zephyris



Heme

Iron Absorption



- Heme iron
  - Found in meats
  - Easily absorbed
- Non-heme iron
  - Absorbed in Fe^{2+} state
  - Aided by vitamin C



Iron Metabolism

- Iron consumed in diet
- Uptake to plasma **regulated by enterocytes**
  - Iron transporter: **ferroportin**
  - Transports iron out of enterocytes and other cells
- Few mechanisms to excrete excess iron
  - Small amount in sweat, sloughing of skin/GI cells
  - Women lose iron from menstruation



Iron Metabolism

- Iron always bound to a protein
- Transport protein: **transferrin**
  - Transported in blood via transferrin
  - ↑ transferrin when iron stores are low
- Storage protein: **ferritin**
  - Stored intracellularly as ferritin
  - Stored in **macrophages** of **liver and bone**

Clinical Iron Measurements

Test	Interpretation
Serum iron	Iron level
Total Iron Binding Capacity	Amount of **transferrin** in serum
Serum ferritin	Amount of storage iron
% saturation	Amount of transferrin bound to Fe

Iron Deficiency

- Lack of iron from gut
- Loss of iron (usually as blood)

Iron Deficiency

Inadequate GI uptake

- **Babies**
  - Iron stores depleted ~ 6months
  - Recommendation: add iron-containing foods
  - Exclusive breast feeding → iron deficiency

Achoubey/Wikipedia

Iron Deficiency

Inadequate GI uptake

- **Malabsorption**
  - Any disease affecting duodenum or acid production
  - Loss of acid → **more Fe3+**
  - Status post gastrectomy
  - Proton pump inhibitors
- Rarely malnutrition

Iron Deficiency

Loss of iron

- **Bleeding**
  - Menorrhagia
  - Peptic ulcers
  - Colon cancer
- **Adult or post-menopausal female with iron deficiency must have work-up for colon cancer**

Iron Deficiency

Other causes

- **Pregnancy**
  - "Negative iron balance" in pregnancy
  - Expansion in mothers Hgb mass
  - ↑ demand of fetal growth
  - Prenatal vitamins often contain **iron and folate**

Øyvind Holmstad/Wikipedia

Pregnancy/OCPs

$$\% \text{ Sat} = \frac{\text{Iron}}{\text{TIBC}}$$

- **Increase plasma transferrin**
- Percent saturation may be low
- **Low ferritin** often used to diagnose iron deficiency



Ceridwen/Wikipedia

Iron Deficiency

Rare causes



Pixabay/Public Domain

- **Hookworms**
  - Consume blood in intestines
  - Ancylostoma duodenale
  - Necator americanus
- **Plummer–Vinson syndrome**
  - Rare condition; poorly understood cause
  - Iron deficiency anemia, beefy red tongue, **esophageal webs**

Iron Deficiency



Iron Deficiency Anemia

- **Microcytic, hypochromic** anemia
  - ↓ RBCs (anemia)
  - Small cells
  - Hypochromic (low hemoglobin)
  - ↓ MCV, MCH, MCHC
- **Initially may be normocytic**
  - Marrow makes fewer RBCs; maintains Hgb

Red Cell Distribution Width

RDW

- Spectrum of RBC size
- Often wider in **iron, B12/Folate deficiency**
  - Normal RDW makes iron deficiency unlikely
- Can be normal in mild thalassemia



Protoporphyrin



- Heme = Iron + protoporphyrin
- **Erythrocyte protoporphyrin level**
  - Rarely used blood test
  - Will be **elevated in iron deficiency**
  - No Fe for protoporphyrin to bind with
- Also elevated in **lead poisoning**
  - Inhibits addition of iron to protoporphyrin
- Major uses: screening
  - Iron deficiency or lead poisoning

Iron Deficiency Anemia

Treatment

- **Iron supplementation**
- Usually oral therapy
- Rarely IV iron can be used

Anemia of Chronic Disease

- Anemia in association with **inflammation**
  - Common in rheumatoid arthritis, lymphoma
  - Many other chronic conditions
- Usually a **mild** anemia (Hgb > 10g/dL)
- Symptoms from anemia are rare

Anemia of Chronic Disease

Mechanisms

- Triggered by **cytokines**
- Mild decrease in RBC survival
- Inadequate EPO level/response
  - Lower EPO than expected for degree of anemia
  - Less increase in RBC production by EPO
- Lack of **availability** of iron
  - Trapped in storage form
  - Key mediator: **hepcidin**

Hepcidin

- Acute phase protein
  - Produced in liver
  - Has anti-bacterial properties
- Affects iron metabolism
  - Inhibits iron transport
  - Binds to **ferroportin** in enterocytes, macrophages
- **Iron trapped in cells as ferritin**
- Contributes to anemia of chronic disease
- Key finding ACD: **↑ ferritin**

Anemia of Chronic Disease

- Usually normocytic/normochromic
- Microcytic/hypochromic in about 25% cases
  - Low iron availability may lead to small red cells
  - MCV usually mildly decreased (70-80)
- Important to distinguish from iron deficiency
  - Does not respond to iron
- First line therapy: **treat underlying disease**

Anemia of Chronic Disease

Diagnosis

- **Serum iron is low**
  - Thought to be protective
  - Bacteria may use iron for growth/metabolism
- **Ferritin is usually increased**
  - Iron trapped in storage form
  - Ferritin is acute phase reactant
  - Increase may not represent increased storage iron
- Transferrin (TIBC) is usually decreased
  - Transferrin rises when total body iron low
- % saturation usually normal

Iron Studies

	Iron	Ferritin	TIBC	% Sat
Iron Deficiency	↓	↓	↑	↓↓
Anemia Chronic Disease	↓	↑	↓	--
Hemochromatosis	↑	↑	↓	↑↑

Elevated when body storage iron is low

Lead Poisoning

- Exposure to lead:
  - Adults: **Inhalation** from industrial work (battery factory)
  - Children: **Eating lead paint** (old house)
- **Inhibits heme synthesis** via two enzymes in RBCs
  - Delta-aminolevulinic acid (δ-ALA) dehydratase
  - Ferrochelatase
- ↓ heme synthesis → microcytic, hypochromic anemia
- Iron studies: **normal or low**

Heme Synthesis



Succinyl-CoA

δ-ALA dehydratase

δ-ALA Synthase

δ-ALA → Porphobilinogen → → → Protoporphyrin

Glycine





Fe^{2+}

Ferrochelatase

Heme



ALA Synthase: Rate-limiting Step

↓ Heme → ↑ ALA Synthase

Build up of: δ-ALA, Protoporphyrin

Lead Poisoning

Diagnosis

- **Plasma lead level**
- ↑ delta-aminolevulinic acid (δ-ALA)
- ↑ erythrocyte protoporphyrin

Lead Poisoning

Diagnosis

- Blood smear: **basophilic stippling**
  - Blue granules in cytoplasm of red cells
  - Lead inhibits pyrimidine 5' nucleotidase
  - Normally digests pyrimidines in ribosomes/RNA
  - Leads to accumulation of pyrimidines/RNA in RBCs
- Also seen in thalassemia, other anemias



isis325/Flikr

Lead Poisoning

Symptoms

- **Abdominal pain** ("lead colic")
- Constipation
- Headache
- **"Lead lines"**
  - Blue pigment at gum-tooth line
  - Caused by reaction of lead with dental plaque
- Nephropathy
  - Injury to proximal tubules (Fanconi-type syndrome)
  - Glucose, amino acids, and phosphate wasting
- Neuropathy
  - Common symptom: Drop wrist and foot

Lead Poisoning

Symptoms

- Children may have prominent neurologic effects
  - **Behavioral issues**
  - Developmental delay
  - Failure to reach milestones (i.e. language)
- Many states screen children with lead level testing
  - Usually at 1-2 years of age

Lead Poisoning

Treatment

- Removal of exposure to lead
- Chelation therapy
  - **Dimercaprol** (2,3-dimercapto-1-propanol)
  - **Calcium disodium EDTA** (ethylenediaminetetraacetate)
  - **DMSA** (2,3-dimercaptosuccinic acid; succimer)

Sideroblastic Anemia

- Ring Sideroblasts:
  - Nucleated red cell precursors
  - **Iron-loaded mitochondria** seen with Prussian blue stain
  - Perinuclear ring of blue granules
- Sideroblastic anemia
  - Usually microcytic anemia
  - Ring sideroblasts in marrow



Paulo Henrique Orlandi Mourao

Sideroblastic Anemia

- **Failure to make protoporphyrin**
- Iron cannot bind → heme
- Iron accumulation in **mitochondria**



Sideroblastic Anemia

- Usually **secondary** to a toxin
  - Alcohol (mitochondrial poison)
  - Vitamin B6 deficiency (Isoniazid)
  - Lead poisoning (controversial)



Sideroblastic Anemia

- **X-linked sideroblastic anemia**
  - Rare, inherited deficiency of ALA synthase
  - Most common hereditary sideroblastic anemia
- Often responds to treatment with **vitamin B6**



Sideroblastic Anemia

Lab Findings

- Microcytic, hypochromic anemia
- Iron studies show **iron overload**
  - ↑ serum iron
  - ↑ ferritin
  - ↓ TIBC (transferrin)
- **Low erythrocyte protoporphyrin levels**

Microcytic Anemias



Thalassemias

Jason Ryan, MD, MPH

Anemia Classification

- MCV commonly used to classify anemias

Microcytic MCV<80	Normocytic MCV 80-100	Macrocytic MCV>100
Iron deficiency	Iron deficiency	Folate/B12 deficiency
Anemia Chronic Disease	Anemia Chronic Disease	Orotic Aciduria
Thalassemia	Hemolysis	Liver disease
Lead poisoning	Aplastic anemia	Alcoholism
Sideroblastic Anemia	Kidney disease	Reticulocytosis

Microcytic Anemias

- Usually due to ↓ **hemoglobin** in red cells
- Usually associated with ↓ MCH and MCHC
- Low hemoglobin → hypochromic RBCs on smear



Thalassemia

- Decreased or absent **production of globin chains**
  - Alpha thalassemia: alpha globin
  - Beta thalassemia: beta globin

Globins and Hemoglobin



All Hgb has two alpha globins
Other chain determines type

Globins and Hemoglobin

Alpha (α)

Beta (β)

Delta (δ)

Gamma (γ)



Hemoglobin A
(95%)
α2 β2

Hemoglobin A2
(<5%)
α2 δ2

Hemoglobin F
Fetal
α2 γ2

All Hgb has two alpha globins
Other pair determines type

Globins and Hemoglobin

Alpha (α)

Beta (β)

Delta (δ)

Gamma (γ)

Hemoglobin A
(95%)
α2 β2

Hemoglobin A2
(<5%)
α2 δ2

Hemoglobin F
Fetal
α2 γ2

All Hgb has two alpha globins
Other pair determines type

Hgb Electrophoresis

- Electrical charge applied to sample on gel
- Different hemoglobin → different distances moved
- Determines HgbA, HgbA2, HgbF, HgbS
- Used to diagnose hemoglobinopathies
  - Thalassemia
  - Sickle cell disease



Mnolf/Wikipedia

Thalassemia

- Spectrum of severity
- Thalassemia **minor**
  - Often asymptomatic
  - Identified on routine blood testing or blood smear
- Thalassemia **major**
  - Severe loss of globin production
  - Lifelong transfusions or death

Alpha Thalassemia



αα/αα

- **Four genes** code for alpha chains
  - Two on each copy of chromosome 16
- **Gene deletions** → ↓α chains → alpha thalassemia



α-/αα



--/αα
-α/-α



--/-α



--/--

Alpha Thalassemia Minima

- Normal red cells
- No symptoms
- Carrier state



α-/αα

Alpha Thalassemia Minor

Alpha Thalassemia Trait

- No symptoms
- Can have normal red cells
- Sometimes mild anemia
  - ↓ MCV/MCH/MCHC



--/αα
-α/-α

Alpha Thalassemia Minor

Alpha Thalassemia Trait

- Common among Asians and Africans
- Alpha minor can be cis (αα/--) or trans (α-/α-)
- Asians more commonly have cis type
- Africans: trans

HbH Disease

- Very little alpha globin production
- Excess beta globin
- HbH forms: **4 beta chains**
  - Easily damaged
  - Affinity for oxygen 10x HbA
  - Useless for oxygen delivery
- HbH forms after birth
  - No β chains in HbF
  - More β produced → HbH



--/-α

HbH Disease

- Hypochromic, microcytic anemia
- Low MCV, MCH, MCHC



--/-α

HbH Disease

- Abnormal RBC **deformability**
- **Extravascular hemolysis**
  - Splenomegaly
  - Indirect hyperbilirubinemia
  - Elevated LDH
- HBH easily oxidized
  - Risk for intravascular hemolysis
  - Occurs with oxidant stressors (infection, drugs)
  - Similar glucose-6-phosphate dehydrogenase deficiency



--/-α

HbH Disease

- Diagnosis: **DNA testing**
- Electrophoresis insensitive
  - Some production A and A2
  - **May see HbH depending on amount**



--/-α

HbH Disease



--/-α

- Treatment:
  - Splenectomy
  - Transfusions
- Long term risk: **iron overload**

Public Domain

Hgb Barts

- **No α globin**
- Cannot form HbF
- Hgb Barts forms in utero
  - **Four gamma globin chains**
- Cannot release oxygen to tissues
  - Affinity for oxygen 10x HbA
- Hydrops fetalis
  - Massive total body edema
  - High output heart failure
- Fetal death usually occurs or death hours after birth



Beta Thalassemia



- ↓ β globin chain synthesis
- **Two genes** code for beta chains
- One on each copy of chromosome 11

Beta Thalassemia



- Often caused by **mutations** (NOT deletions)
- Wide spectrum of disease depending on mutation
  - β^{o} = no function; β^{1} = some function

Beta Thalassemia
Minor



+/-

Beta Thalassemia
Major



-/-

Beta Thalassemia

Beta Thalassemia Minor



- Also called beta thalassemia trait
- Heterozygotes: single abnormal gene
- Reduced β globin production
- **Asymptomatic**
- May see mild anemia on routine blood work
- Diagnosis by **electrophoresis**
  - **↑ HgbA2 (α2δ2 – no beta chains)**
  - Normal <5%

Beta Thalassemia Major

Cooley's Anemia

- No or severely limited β globin production
- Anemia beginning **1st year of life**
  - HgbF (α2γ2) production wanes
- Ineffective erythropoiesis
  - Alpha chains form tetramers
  - Precipitate → RBC damage
  - Failure to produce RBCs
- Splenomegaly
  - Spleen clears any abnormal RBCs in plasma



Beta Thalassemia Major

Cooley's Anemia

- Hypochromic, microcytic anemia
- Abnormal red blood cells shapes
- Erythroid hyperplasia
- Extramedullary hematopoiesis



RBC Abnormalities

- Microcytosis (small RBCs)
- Hypochromia (loss of Hgb)
- Anisocytosis
  - Wide variation in sizes of RBCs
  - Increased red cell distribution width (RDW)
- Poikilocytosis (abnormal shapes)
- Basophilic stippling
- Nucleated RBCs
- Target cells

Basophilic Stippling

- Residual RNA in red cells
- Often seen with nucleated RBC
- Seen in thalassemia
- Also lead poisoning



Prasad CSBR



isis325/Flikr

Target Cells

- Target formed in center of RBC
  - Small dark area in center of cell
- Due to **↑ surface area-to-volume ratio**
- Extra cell membrane → target appearance



Dr Graham Beards

Target Cells

- Decreased cell volume
  - **Thalassemia**
  - Can be seen in iron deficiency
- Increased cell membrane
  - Liver disease (↑ cholesterol in membrane)
  - Splenic dysfunction (↓ removal excess membranes)

Erythroid Hyperplasia

- Massive expansion of bone marrow
- ↑↑ EPO without normal response
- Consequence of severe anemia in beta major disease
- Abnormalities of skull and facial bones
  - **"Chipmunk facies"**
  - **Crew cut appearance** of skull on x-ray
- Delayed skeletal maturation
- Widening of marrow spaces → osteoporosis

Extramedullary hematopoiesis

- Hematopoiesis **outside of bone marrow**
- Consequence of severe anemia in beta major disease
- Liver and spleen produce RBCs
- **Hepatosplenomegaly**
- Often produces **nucleated RBCs**

Parvovirus B19

- Infection may cause aplastic crisis
- Beta major patients highly dependent bone marrow

B19

Beta Thalassemia Major

Cooley's Anemia

- Diagnosis: **Electrophoresis**
- Increased Hgb forms that do not require beta chains
- ↓ or absent HbA ($\alpha_2\beta_2$)
- ↑ HbA2 ($\alpha_2\delta_2$)
- ↑ HbF ($\alpha_2\gamma_2$)

Beta Thalassemia Major

Cooley's Anemia

- Treatment: **Blood transfusions**
- Long term risk: **iron overload**

Public Domain

Beta Thalassemia Intermedia

- **Symptomatic** beta thalassemia
- Does not require transfusions
- Chronic hemolytic anemia
- Bone marrow expansion
- Hepatosplenomegaly

Malaria

- Alpha and beta thalassemia protective vs. malaria
- ↓ growth in RBCs of **plasmodium falciparum**

Trophozoite Ring



CDC/Public Domain

Red Cell Distribution Width

RDW

- Spectrum of RBC size
- Wider in **iron deficiency**
- Can be normal in mild thalassemia
- Normal RDW makes iron deficiency unlikely



Thalassemia

Key Points



Sickle Cell Anemia

Jason Ryan, MD, MPH

Normocytic Anemias



Sickle Cell Anemia

- Autosomal recessive disorder
- **Abnormal β hemoglobin chains**
  - Beta chains found in hemoglobin A (α2 β2)
  - Makes up 95% of Hgb

Sickle Cell Anemia



- Root cause is abnormal beta globin gene
- **Single base substitution** 6th codon of β gene
- Adenine changed to thymine
- Abnormal genes produce HbS



Sickle Cell Anemia

- Substitution of **valine** for **glutamate** in beta chains
  - Glutamate: polar (hydrophilic)
  - Valine: non-polar (hydrophobic)
- Alters shape of beta chains



Valine
(HbS)



Glutamate
(Normal Hgb)

Globins and Hemoglobin

Alpha (α)

Beta (β)

Delta (δ)

Gamma (γ)



Hemoglobin A
(95%)
α2 β2

Hemoglobin A2
(<5%)
α2 δ2

Hemoglobin F
Fetal
α2 γ2

In utero and at birth: ↑ HbF ↓ HbA

Sickle Cell Anemia

- Deoxygenated HbS is poorly soluble
- **Polymerization** when O2 low
  - Also in dehydration, acidosis
- Red blood cells form crescents
- Appearance of a sickle
- Causes a ↓ ESR



Madboy74



Scooterdmu/Flikr

Sickle Cell Anemia

- Two major problems result from sickle cells
- #1: **Hemolytic anemia**
- #2: **Vaso-occlusion of small blood vessels**

Sickle Cell Anemia

Hemolysis

- Sickling is reversible
- Cells continuously sickle/de-sickle in circulation
- Over time this leads to **RBC membrane damage**
- Results in **extravascular hemolysis**
  - Anemia
  - Jaundice
  - Elevated unconjugated bilirubin
  - Pigment gallstones
- Some intravascular hemolysis may also occur

Sickle Cell Anemia

Erythroid Hyperplasia

- ↑↑ EPO
- Massive expansion of bone marrow
- Consequence of severe anemia:
  - Also seen in beta thalassemia major
- Abnormalities of skull and facial bones
  - **"Chipmunk facies"**
  - **Crew cut appearance** of skull on x-ray
- Delayed skeletal maturation
- Widening of marrow spaces → osteoporosis

Sickle Cell Anemia

Parvovirus B19

- Infection may cause aplastic crisis
- Crisis also seen in spherocytosis, thalassemia

B19

Sickle Cell Anemia

Vaso-occlusion

- Sickle cells may **occlude microvasculature**
- May affect any organ
- Classic clinical manifestation:
  - Swollen hands ("dactylitis")
  - Acute pain crises
  - Spleen failure → infections
  - Acute chest syndrome
  - Renal dysfunction

Sickle Cell Anemia

Dactylitis

- Pain/swelling in hands or feet
- Fingers may look like “sausage” digits
- Common initial symptom among children

Sickle Cell Anemia

Avascular Necrosis

- Bone collapse
- Most commonly **femoral head**
- Also associated with long term steroid use



Jmarchn/Wikipedia

Sickle Cell Anemia

Pain Crises

- Episodes of acute pain ("sickle cell crisis")
  - Sudden onset of pain
- Most common type of vaso-occlusive event
- May affect any part of body
  - Abdomen, bones, joints, soft tissue, fingers, toes
  - Swollen hands and/or feet especially in children
- Treatment: Hydration and pain medications

Sickle Cell Anemia

Splenic Failure

- Repeated splenic infarctions → functional asplenia
  - Early in disease: splenomegaly (macrophage hyperplasia)
  - Late in disease: Fibrosis and atrophy
- Howell-Jolly bodies will appear in peripheral blood



Paulo Henrique Orlandi Mourao /Mikael Häggström

Sickle Cell Anemia

Splenic Failure

- Increased risk of infections by encapsulated bacteria
- Strep pneumoniae and H influenza
  - Bacteremia/sepsis from S. Pneumoniae
  - Patients must be vaccinated
- Osteomyelitis from Salmonella species
  - Infection of infarcted bones
  - Most common cause SCA is Salmonella (usually S. Aureus)

Sickle Cell Anemia

Splenic Sequestration Crisis

- Vaso-occlusion in spleen → **pooling of red cells**
- Marked fall in hemoglobin level
- Rapidly enlarging spleen
- Risk of hypovolemic shock **especially in children**
  - Occurs in spleens yet to develop fibrosis
  - May occur before sickle cell disease is diagnosed

Sickle Cell Anemia

Chest Syndrome

- Leading cause of death in adults with SCD
- Vaso-occlusion of pulmonary microvasculature
- Often triggered by infection (pneumonia)
  - Increased sickling in lungs
  - Once begun → inflammation/acidosis → more sickling

Sickle Cell Anemia

Chest Syndrome

- Chest pain and shortness of breath
- Infiltrate on chest x-ray
- Looks like pneumonia
- Treatment:
  - Fluids and pain medication (similar to pain crisis)
  - Antibiotics, oxygen, bronchodilators
  - Transfusions as needed

Sickle Cell Anemia

Renal Dysfunction

- Occlusion of **vasa recta in renal medulla**
  - Medulla has low oxygen and high osmolality
  - Promotes sickling
- May impair concentrating ability
  - Cannot raise urine osmolality even with H_20 deprivation
  - Causes nocturia and polyuria

The Nephron



Sickle Cell Anemia

Renal Dysfunction

- Papillary necrosis
  - Sloughing of renal papilla due to renal vaso-occlusion
  - Usually painless
  - Gross hematuria and proteinuria



Image courtesy of Piotr Michał Jaworski

Sickle Cell Anemia

Treatment

- Immunizations
- Hydroxyurea
  - Raises amount of HbF
  - Mechanism unclear
- Transfusions
  - Iron overload may develop
- Bone marrow transplant is curative
- Median survival 42-48 years

Sickle Cell Trait

- One mutated beta globin gene
- Usually no sickling
  - Normal beta gene more effective → >50% beta globins
  - Need >50% HbS for sickling
- One exception: **Renal medulla**
  - May see loss of concentrating ability
  - ↑ risk of **renal medullary carcinoma** (> than sickle disease)



Sickle Cell Diagnosis

Disease or Trait

- Electrophoresis
  - Will show presence of HbS
  - Different amounts disease versus trait
- Sickling Test
  - Sodium metabisulphite reduces the oxygen tension
  - HbS becomes insoluble
  - Forms a turbid suspension → easily visualized
  - Other hemoglobin types remain in solution
  - Positive if any amount HbS present (disease or trait)

Electrophoresis

	Normal	Sickle Cell Disease	Sickle Cell Trait
HbA	97%	--	55%
HbA2	2%	2%	2%
HbF	1%	2-15%	1%
HbS	--	~90%	40%

Malaria

- Sickle trait **protective against p. falciparum**
  - Cells sickle when infected → ↑ clearance
  - **Does not protect against infection**
  - When infection does occur it is milder
  - Patients still need malaria prophylaxis
- African Americans: 8 to 10% have sickle cell trait
- Sub-Saharan Africa: ~30%

Sickle Cell/Beta Thalassemia

- One beta gene: sickle cell
- One beta gene: beta thalassemia
- Clinical manifestations similar to sickle cell
  - Vary depending on beta thalassemia gene function
  - β^o: Similar to sickle cell disease
  - β^1: Less severe



Hemoglobin C

- Rare mutation of beta gene (different from SCA)
- Glutamic acid replaced by lysine (not valine)
- Heterozygotes: Mild anemia (extravascular hemolysis)



Lysine



Glutamate

Hemoglobin C

- Presence of **HbC crystals** on smear
- Induces red cell dehydration: **↑ MCHC**



Isis325/Flikr

Hemoglobin SC

- One HbS gene plus one HbC gene
- More common than homozygous HbC disease
- At risk for same complications as sickle cell disease
- Lower frequency of complications

Other Anemias

Jason Ryan, MD, MPH

Anemias

- Microcytic
- Normocytic, hemolytic
- Normocytic, non-hemolytic
- Macrocytic

Normocytic Anemias



EPO

Erythropoietin

- Synthesized in the kidney
  - Interstitial cells peritubular capillary
  - Found in cortex of the kidney
- Released in response to hypoxia
- Decreased production in renal failure
- Results in a **normocytic anemia**



Madhero88/Wikipedia

Kidney Anatomy



Boards&Beyond STUDY SMARTER

Image courtesy of BruceBlaus

EPO Injections

- Darbepoetin alfa (Aranesp)
- Epoetin alfa (Epogen)
- Used to treat anemia of chronic kidney disease
- FDA Black Box warning
- Generally reserved for patients with severe anemia

Aplastic Anemia

- **Loss of hematopoietic precursors** in bone marrow
- Results in pancytopenia
  - ↓ WBC, ↓ Platelets, ↓ RBC

Vocabulary

- "Aplasia": Defective or absent development
- Bone marrow failure
  - Bone marrow cannot produce cells
  - Results in pancytopenia
  - Many causes: fibrosis, tumors
  - "Myelophthisis:" displacement of bone-marrow tissue
- Aplastic anemia:
  - Specific type of bone marrow failure
  - Defective stem cells → acellular/hypocellular bone marrow

Aplastic Anemia

Hallmarks

- Pancytopenia
- Acellular or hypocellular bone marrow
  - Bone marrow biopsy for diagnosis
  - Absence of cells/replacement with fat



Chalin Drosera

Aplastic Anemia

Symptoms

- **Pancytopenia** (normal cells but not enough)
- Anemia
  - Fatigue, pallor
- Thrombocytopenia
  - Bleeding
- Leukopenia
  - Infections

Aplastic Anemia

Causes

- Most commonly **idiopathic**
- Radiation
- Drugs
- Viruses
- Inherited (Fanconi anemia)

Aplastic Anemia

Idiopathic

- Unknown trigger
- Strong evidence for **immune mediated mechanism**
- **T-cell mediated** destruction of stem cells

Aplastic Anemia

Idiopathic

- Can be treated with immunosuppression
- **Antithymocyte globulin**
  - Animal-derived antibodies against human T cells
  - Usually from rabbits or horses
  - Also can be used in kidney transplant patients
- **Cyclosporine**

Aplastic Anemia

Radiation

- Well-described cause of aplastic anemia
- Radiation → damage to stem cells → aplastic anemia



Public Domain

Aplastic Anemia

Chemicals

- **Benzene**: well-described cause of aplastic anemia
- Rubber factories, shoe repair shops
- Often with poor ventilation



Aplastic Anemia

Drugs

- Most cancer therapies
  - Anticipated effect
- **Chloramphenicol**
  - Rarely used antibiotic (bacterial protein synthesis inhibitor)
- Phenylbutazone
  - Old NSAID
  - Pulled from market due to cases of aplastic anemia
- **Methimazole, Propylthiouracil (PTU)**
  - Aplastic anemia cases reported (monitor WBCs)

Aplastic Anemia

Viruses

- **Parvovirus B19**
  - Infects proerythroblasts
  - Usually causes ↓ RBCs ("red cell aplasia")
  - Pancytopenia can occur
  - ↑ risk: immunocompromised

Aplastic Anemia

Viruses

- **Acute Viral Hepatitis**
  - Can cause aplastic anemia
  - Reported after infection with HAV, HBV, HCV, HDV, and HEV
  - Often affects boys and young adult males
  - Aplasia develops weeks to months after acute hepatitis
- Others: HIV, EBV, CMV
- All probably NOT caused directly by virus
- Evidence suggests T-cell activation

Fanconi Anemia

- Inherited aplastic anemia
- Autosomal recessive or X-linked
- Usually presents in children <16 years old
- More than half of patients have **physical deformities**
  - Short stature
  - Cafe-au-lait spots
  - **Malformed thumbs**
  - Heart, renal, eye abnormalities described

Fanconi Anemia

- More than 13 genetic abnormalities identified
- Many involve **DNA repair enzymes**
  - Hypersensitivity to DNA damage
  - Especially vulnerable to abnormal DNA strand cross-links
- Increased risk of **malignancies**
  - Myelodysplastic syndrome (MDS)
  - Acute myeloid leukemia (AML)
  - Squamous cell carcinoma of head, neck or vulva

Aplastic Anemia

Treatment

- Stop offending agent
- Transfusions (red cells, platelets)
- Bone marrow stimulation
  - EPO, GM-CSF, G-CSF
- Immunosuppression
  - **Antithymocyte globulin**
  - **Cyclosporine**
- Bone marrow transplant

Pure Red Cell Aplasia

- Absence of erythroid precursors in bone marrow
- Marked reduction in reticulocytes
- Normal granulocytes, platelets
- Usually idiopathic
- Associated with some drugs, viral infections
- **Key association: Thymoma**
  - Present in 5 percent of PRCA cases

Macrocytic Anemias

- MCV > 100
- Abnormal DNA synthesis
  - “Megaloblastic anemias”
- Other
  - Liver disease, alcohol, reticulocytosis

Megaloblastic anemias

- Red blood cell precursors grow but cannot divide
  - Contrast with microcytic anemias: divide too much
- Results from **abnormal DNA synthesis**
  - Cells cannot efficiently make DNA for cellular division

Megaloblastic Anemias

- Anemia (↓Hct)
- Large RBCs (↑MCV)
- **Hypersegmented neutrophils**
  - WBCs also cannot divide effectively due to ↓DNA synthesis
  - Result: hypersegmentation of nucleus (>5 lobes)



Wikipedia/Public Domain

Megaloblastic Anemias

- Causes of defective DNA production
  - **Folate deficiency**
  - **B12**
  - Orotic aciduria
  - Drugs (MTX, 5-FU, hydroxyurea)
  - Zidovudine (HIV NRTIs)



Wikipedia/Public Domain

Macrocytic Anemias

Non-megaloblastic

- Macrocytosis without impaired DNA synthesis
- **Liver disease**
  - Exact mechanism not known
  - Increased lipids seen in red cell membranes
- **Alcoholism**
  - Common cause of macrocytosis
  - Acetaldehyde may induce membrane changes in RBCs



Ethanol Acetaldehyde

Reticulocytosis

- Reticulocytes have MCV of 103 to 126fl
- Normal RBCs: 80 to 96 fL
- In theory **may cause macrocytosis**
  - But only about 20% bigger than normal cells
  - Need LOTS of reticulocytes to raise average MCV >100
  - Usually raise average MCV but should not reach >100

Blood Groups

Jason Ryan, MD, MPH

Blood Groups

- Antibodies form to RBC antigens
- "Blood group" defined by RBC antigens
- Important for safely administering blood transfusions
- Must match transfusion to "blood type"
- Two major blood groupings:
  - **ABO system**
  - **Rh system**

ABO System

- A and B antigens can be found on RBCs
- Patients who lack A or B generate antibodies
  - Appear in blood by 4-6 months
  - Exposure to **bacterial antigens** with similar structure
  - Occurs as the gut becomes colonized
- Antibodies: IgM
- Do not cross placenta
- Key point: A and B antibodies are **naturally occurring**

ABO System

	Group A	Group B	Group AB	Group O
Red blood cell type				
Antibodies in Plasma	Anti-B	Anti-A	None	Anti-A and Anti-B
Antigens in Red Blood Cell	A antigen	B antigen	A and B antigens	None

ABO System



InvictaHOG/Wikipedia/Public Domain

Rh System

- Most important blood group system after ABO
- More than 50 antigens are part of Rh system
  - Names for letters following AB: C, D, E
- All are **transmembrane proteins**

Rh System

- **Presence/absence of D antigen is critical**
  - D antigen **highly immunogenic**
  - "Rh positive:" has the D antigen (of the Rh system)
  - "Rh negative:" lacks the D antigen (of the Rh system)
- Other Rh antigens not routinely tested: C, c, E, e

Rh System

- **Rh positivity is common**
  - Caucasians: 83%
  - Some Asian populations: 98%
- Rh negative may develop anti-D antibodies
- Only happens if **exposed to D^+ RBC**
  - Transfusion
  - Pregnancy (Mom D^- with baby D^+)
- Anti-D antibodies: **IgG**
- May cross placenta

Newborn Hemolytic Disease

- Classically caused by **anti-D (anti-Rh) antibodies**
- Can only occur in **D^- mother with D^+ baby**
- D^- mother capable of developing anti-D antibodies
- If father is D^+: baby may also be D^+

Newborn Hemolytic Disease

- First pregnancy: Mother exposed D^+ RBCs **at delivery**
- 2^{nd} pregnancy: Anti-D IgG in mother → fetus
- If 2^{nd} baby also D^+ hemolysis will occur in utero

Newborn Hemolytic Disease

- Mild cases present as hemolytic anemia
- Severe cases: **Hydrops fetalis**
- Massive **edema**: Pleural/pericardial effusion, ascites
- Mechanisms:
  - High-output congestive heart failure
  - ↑ RBC production by spleen/liver → obstruction
  - Results in portal hypertension
- Seen in other severe anemias of newborns
  - Hgb Barts (lack of alpha globins)

Maternal Antibody Screening

Indirect Coombs Test



"Isoimmunization"

Newborn Hemolytic Disease

Prevention

- Anti-D immune globulin ("RhoGAM")
- IgG **antibodies to D antigen**
- Rapid macrophage clearance of D^+ RBCs
- Given in 3rd trimester to D^- women
- Blocks/prevents isoimmunization



Other Antigens

- Only ABO and Rh routinely tested
- Many other antigens on RBCs
- Only tested when patient has abnormal screening test
- Antibodies from **pregnancy or transfusion**



Transfusion Medicine

Common Tests

- Blood type (usually done with another test)
- Type and screen
  - Antibody screening test
  - Further testing if positive
- Type and crossmatch ("type and cross")
  - Matching of donor blood to patient

Blood Type Testing

- **Patient RBCs** plus antibodies
  - Anti-A; Anti-B; Anti-D
- **Agglutination** indicates presence of antigen

Blood Type Testing



Type and Screen

- **Recipient serum** plus standard RBCs
- Screen for patient antibodies to rare antigens
- Will only have antibodies if prior exposure
- **Reagent RBCs** contain many RBC antigens
  - No agglutination: Patient lacks antibodies
  - Agglutination: Antibodies to less common antigens present

Type and Screen



Abnormal Screen

- Determine **which antibody is present**
- Test patient's serum against large panel of antigens
- Subsequent transfusions: Test donor blood for antigen
- Challenging in patients with long transfusion history
  - Sickle cell anemia
  - Beta thalassemia major
- Key point: **Don't transfuse unless necessary**

Type and Cross

- **Patient serum** with potential **donor RBCs**
- Final test of product to be transfused



Blood Products

- **Packed RBCs**
  - RBCs with plasma removed
  - Usually administered instead of “whole blood”
  - Minimizes volume given to patient
- **Platelets**
  - Express ABO and HLA class I antigens
  - Do not express Rh or HLA class II
  - Reactions from mismatch less common that with RBCs

Blood Products

- **Fresh Frozen Plasma (FFP)**
  - Plasma after removal of RBC, WBC, and platelets
  - Frozen for storage
  - Once thawed, must be used within 24hrs
  - Clotting factors degrade
  - Corrects deficiencies of any clotting factor
  - PT/PTT will normalize after infusion
- **Cryoprecipitate**
  - Precipitate that forms when FFP is thawed
  - Contains lots of **fibrinogen**
  - Massive bleeding or rare ↓ fibrinogen disorders

Transfusion Reactions

- Acute hemolytic reaction
- Anaphylaxis
- Febrile reaction
- TRALI
- Many, many other potential reactions
  - Heart failure
  - Sepsis

AHTR

Acute hemolytic transfusion reaction

- Feared complication of blood transfusion
- Pre-formed antibodies → donor RBCs
  - **Type II hypersensitivity reaction**
  - Usually from transfusion of **incorrect blood product**

AHTR

Acute hemolytic transfusion reaction

- Life-threatening reaction
- **Acute hemolysis** of transfused RBCs
  - Intravascular (complement; anti-AB are IgM)
  - Extravascular (spleen)
- Can lead to DIC
- Fever, chills, flank pain, oozing from intravenous sites
- Jaundice, elevated bilirubin → dark urine
- Direct antiglobulin test (Coombs) will be positive

AHTR

Acute hemolytic transfusion reaction

- Usual cause: **system or clerical error**
- Transfusion of wrong blood product
- Numerous safety measures used to prevent:
  - Blood type, antibody screen, cross match
  - Careful patient identification

Anaphylaxis

- Allergic reaction (type I hypersensitivity)
- Hives, angioedema, wheezing, hypotension
- May occur in **IgA-deficient individuals**
  - Produce anti-IgA antibodies
  - React with IgA in transfused product
- Also occurs to plasma proteins in transfused product
- Treatment:
  - Stop transfusion
  - Epinephrine, anti-histamines

FNHTR

Febrile non-hemolytic transfusion reaction

- Fever, chills
- No other systemic symptoms
- Caused by **cytokines** in blood products
  - Especially IL-1
  - Generated by WBCs during storage
  - Accumulate in stored blood components
- Some blood products undergo "**leukoreduction**"

TRALI

Transfusion-related acute lung injury

- Sudden onset hypoxemia during transfusion
- Inflammatory reaction: Fever, chills are common
- Infiltrates on chest x-ray
- Results from **neutrophil activation** by blood products
  - Some patients predisposed with PMNs in lungs
  - PMNs release cytokines, reactive oxygen species, enzymes
  - Damage the pulmonary capillary endothelium
  - Exudative fluid loss → pulmonary edema

Transfusion Reaction

- Any suspected reaction: **STOP TRANSFUSION**

Acute Leukemias

Jason Ryan, MD, MPH

Leukemia

- Malignant proliferation of white blood cells
- Cells appear in blood (contrast with lymphoma)
- **Increased WBC**

Leukemias

Classification

- Myeloid versus lymphoid
- Acute versus chronic
- Acute
  - Rapid onset of symptoms
  - Involves **blasts** in bone marrow
- Chronic
  - Slower onset of symptoms (or no symptoms)
  - Malignant cells are not blasts (more mature)

Hematopoiesis



Mikael Häggström /Wikipedia

Myeloid Disorders



Lymphoid Disorders



ALL

Acute Lymphoblastic Leukemia

- Disease of children
  - Peak incidence ~ 4 years old
- Fever
- **Bone pain** (marrow expansion)
- Lymphadenopathy, splenomegaly, hepatomegaly
  - Infiltration by malignant cells
- **Headache, vomiting**
  - Meningeal spread
- May cause bone marrow depression
  - Anemia, thrombocytopenia, neutropenia

ALL

Acute Lymphoblastic Leukemia

- Peripheral blood: lymphoblasts
  - Can appear similar to myeloblasts
  - Special testing distinguish from myeloblasts



VashiDonsk /Wikipedia

Lymphocyte Development



Lymphocyte Antigens

Primarily T-Cell Associated	Primarily B-cell Associated
CD1 CD2 CD3 CD4 CD5 CD7 CD8	CD10 CD19 CD20 CD21 CD22 CD23

ALL

Acute Lymphoblastic Leukemia

- Usually pre-B cell malignancy (~70 to 80% cases)
  - **CD10+**
  - "Common acute lymphoblastic leukemia antigen" or "CALLA"
  - Also CD19+, sometimes CD20+
- Terminal dexoytransferase (TdT)
  - DNA polymerase (found in nucleus)
  - Found only in pre-B and pre-T blasts
  - NOT seen in myeloblasts

ALL

Acute Lymphoblastic Leukemia

- Treated with chemotherapy
  - Cure rates >80% in many studies
- "Sanctuary sites"
  - Poor penetration by chemotherapy drugs
  - Relapse may occur in these locations
- **Testes**
- **Central nervous system**
- Special treatments (radiation/chemo) used
- Sterility may occur in boys

ALL

Acute Lymphoblastic Leukemia

- Many different translocations reported in B-ALL
- Philadelphia chromosome t(9;22)
  - 20 to 30% ALL in **adults**
  - 2 to 3 % ALL in children
  - Associated with a **poor prognosis**
- t(12;21)
  - Fusion product of two genes: TEL-AML1
  - TEL-AML1 impairs differentiation of blasts
  - **Good prognosis**
  - Most common rearrangement in children

ALL

Acute Lymphoblastic Leukemia

- **Down Syndrome**
  - Risk of ALL ↑↑ 10-20x
  - 1-3% ALL cases have Down

Vanellus Foto/Wikipedia

T-Cell ALL

T-cell acute Lymphoblastic Leukemia

- Less common form of ALL
- Common in adolescent males (teens to 20s)
- Presents as a **mass**
  - Lymphadenopathy
  - **Mediastinal mass**
  - Anterior with pleural effusions
- Tumor compression may occur
  - Superior vena cava syndrome
  - Tracheal obstruction



G. Ferretti

T-Cell ALL

T-cell acute Lymphoblastic Leukemia

- Pathology: Blasts
- Different markers from B-cell ALL
  - Usually CD7+
  - Can see CD2, CD3, CD5, CD4, CD8
  - Not CD10+

AML

Acute Myelogenous Leukemia

- Malignancy of myeloblasts
- Common in adult males
  - Median age at diagnosis: 65
  - Male:female ratio: 5:3
- Symptoms from **bone marrow suppression**
  - Myeloblasts accumulate in marrow, suppress cell growth
  - Anemia: Fatigue, weakness, pallor
  - Thrombocytopenia: Bleeding (especially gums)
  - Neutropenia: Infections
- Enlarged nodes, spleen, liver less common than ALL

AML

Acute Myelogenous Leukemia

- Peripheral blood smear
  - Anemia, thrombocytopenia, blasts
- Myeloblasts
  - Myeloperoxidase (MPO) positive
  - Auer rods



Paulo Henrique Orlandi Mourao/Wikipedia

Auer Rods

- Pathognomonic AML
- Accumulation of MPO
- Can cause DIC



Paulo Henrique Orlandi Mourao/Wikipedia

AML

Acute Myelogenous Leukemia

- Classified into numerous subtypes (WHO system)
- Classified by morphology, surface markers, genetics
- Key subtype: **APML**

APML

Acute Promyelocytic Leukemia

- Defined by translocation t(15;17)
  - Creates a fusion gene: PML-RARA
  - Promyelocytic leukemia gene (chromosome 15)
  - **Retinoic acid receptor** alpha (chromosome 17)

APML

Acute Promyelocytic Leukemia

- #1: **Abnormal retinoic acid receptor (RAR)**
  - Prevents normal maturation of promyelocytes
  - Treatment: all trans retinoic acid (form of vitamin A)
  - Abnormal cells will mature

APML

Acute Promyelocytic Leukemia

- #2: **Disseminated intravascular coagulation**
  - Promyelocytes contains lots of MPO (Auer rods common)
  - Release → DIC (common initial presentation)

Myelodysplasia

Myelodysplastic Syndromes (MDS)



VashiDonsk /Wikipedia

- Abnormal **myeloid** progenitor cells
- Leads to ineffective hematopoiesis
  - Anemia, thrombocytopenia, neutropenia
- Diagnosis: Bone marrow biopsy
  - Dysplasia (abnormal) cells
  - Blasts <20% cells
- Can progress to AML (>20% blasts)

MDS
<20% cells
blasts

AML
>20% cells
blasts

Myelodysplasia

Myelodysplastic Syndrome (MDS)

- Associated with **environmental factors**
  - Prior radiation
  - Chemotherapy
  - Usually years after exposure



Dina Wakulchik/Wikipedia



Jenny Mealing/Wikipedia

Chronic Leukemias

Jason Ryan, MD, MPH

Leukemia

- Malignant proliferation of white blood cells
- Cells appear in blood (contrast with lymphoma)
- **Increased WBC**

Leukemias

Classification

- Myeloid versus lymphoid
- Acute versus chronic
- Acute
  - Rapid onset of symptoms
  - Involves **blasts** in bone marrow
- Chronic
  - Slower onset of symptoms (or no symptoms)
  - Malignant cells are not blasts (more mature)

Myeloid Disorders



CML

Chronic Myelogenous Leukemia

- Malignant disorder of myeloid progenitor cells
- Dysregulated production of **granulocytes**
  - Neutrophils, basophils, eosinophils
- Classified as a myeloproliferative disorder



CML

Chronic Myelogenous Leukemia

- Peripheral blood (chronic phase):
  - Leukocytosis (median WBC 100,000/microL)
  - ↑ neutrophils
  - ↑ myeloblasts, promyelocytes, myeolcytes, bands
  - ↑ **basophils** (rare finding!)
  - ↑ eosinophils
- Mild anemia; normal or increased platelets



Paulo Henrique Orlandi Mourao/Wikipedia

CML

Chronic Myelogenous Leukemia

- Chronic phase (usually years)
  - Can be asymptomatic (↑WBC on blood testing)
  - Fatigue, malaise, weight loss, splenomegaly
  - Few blasts (usually <2%)
- Accelerated phase (usually months)
  - Treatment failure (rising WBC)
- Blast crisis
  - Acute leukemia (>20% blasts in periphery or marrow)
  - Usually myeloblasts (AML)
  - Less commonly lymphoblasts (ALL)

Left Shift

Leukemoid Reaction

- Normal response to infection
- More bands and neutrophils
- Must be distinguished from CML

	Normal	Infection
WBC	10,000/µL	17,000 /µL
Neutrophils	55%	80%
Bands	5%	12%

LAP

Leukocyte Alkaline Phosphatase

- Enzyme found in normal neutrophils
- Absent in neutrophils of CML
- Enzyme level assessed with **LAP score**
  - Low = CML
  - High = Leukemoid reaction
- Largely replaced by testing for Ph chromosome

Philadelphia Chromosome

- Genetic hallmark of CML
- 9;22 translocation
- BCR-ABL fusion gene
- Synthesis **tyrosine kinase** protein
- Long cell life → accumulation



Aryn89/Wikipedia

Tyrosine Kinase Inhibitors

Imatinib, Dasatinib, Nilotinib

- Used for treatment in CML (chronic phase)
- Long term control of disease (not curative)
- Bone marrow transplant often used after failure



ProjectManhattan/Wikipedia

CLL

Chronic Lymphocytic Leukemia

- Disorder of naïve lymphocytes
  - Not blasts
  - Newly produced by bone marrow
- Characteristic immunophenotype
  - **CD5+ B cells**
  - "Co-express CD20 and CD5"

SLL

Small lymphocytic lymphoma

- Same malignant cells as CLL
- Differentiated by degree of lymphocytosis (↑WBC)
- CLL: Increased WBC
- SLL: normal or mild lymphocytosis
- SLL definition: lymphocyte count of <5000
- CLL definition: lymphocyte count of >5000

CLL

Chronic Lymphocytic Leukemia

- Median age 60
- Patients often **asymptomatic**
  - Routine CBC: Increased lymphocytes
  - 5-10% of patients have B symptoms (fevers, sweats)
- Signs
  - Lymphadenopathy, splenomegaly, hepatomegaly
- Many patients observed without treatment

CLL

Chronic Lymphocytic Leukemia

- Smudge cells
  - Peripheral lymphocytes are fragile
  - Disrupted during preparation of blood smear



Paulo Henrique Orlandi Mourao/Wikipedia

CLL

Chronic Lymphocytic Leukemia

- B-cell disruption
- Hypogammaglobulinemia
  - Usually ↓ IgG, IgA, IgM
  - **Increased susceptibility to bacterial infections**
- Autoantibodies
  - **Not produced by malignant cells**
  - Produced by non-neoplastic cells (self-reactive)
  - Autoimmune hemolytic anemia

CLL

Chronic Lymphocytic Leukemia

- May transform into **diffuse large B cell lymphoma**
- Classic presentation
  - Patient with known CLL
  - Rapid growth of single lymph node
  - Biopsy: diffuse large B cell lymphoma

Hairy Cell Leukemia

- Rare chronic B-cell malignancy
  - Express CD19, CD20, CD22
  - CD103: sensitive marker
- Peripheral smear: hairy cells
  - Lymphocytes
  - Hair-like cytoplasm projections



Paulo Henrique Orlandi Mourao/Wikipedia

Hairy Cell Leukemia

Unique Features

- Massive **splenomegaly**
  - **Red pulp** engorged
  - Atrophy or obliteration of white pulp
- **"Dry tap"** on bone marrow biopsy
  - Hairy cells induce marrow fibrosis
- **Tartrate-resistant acid phosphatase (TRAP)**
  - Cellular enzyme
  - Hairy cells: strong positivity for TRAP staining

Spleen



Hairy Cell Leukemia

Clinical features

- Median age: 52
- Presenting feature often **abdominal pain**
- Fatigue, weakness
- Splenomegaly
- Bone marrow suppression (anemia, ↓platelets)

Cladribine

2-chlorodeoxyadenosine (2-CdA)

- Preferred initial therapy for HCL
- Excellent clinical response
- Similar to adenosine ("**purine analog**")
- Highly toxic to leukemic cells in HCL



Cladribine



Deoxyadenosine

Hodgkin Lymphoma

Jason Ryan, MD, MPH

Lymphomas

- Malignancies of lymphocytes (B cells, T cells)
- Often involve **lymph nodes**
- Also “extranodal” (skin, GI tract)



Wikipedia/Public Domain

Lymphomas

Signs and Symptoms

- Enlarged, **painless** lymph nodes
- "B symptoms"
  - Systemic symptoms
  - Fever, chills, night sweats

Lymphomas



Reed-Sternberg Cells

- Large cell
- Multi-lobed nucleus
  - Two halves; often mirror images ("owl-eyed")
- Usually derive from **B cells** (rarely from T cells)
- Usually **CD15+ and CD30+**
- Usually NOT positive for B cell markers
  - CD19, CD20, CD21, CD22
- Sometimes seen in other disorders

Reed-Sternberg Cells



Nva1991/Wikipedia

Hodgkin Lymphoma

- Malignant cell: Reed-Sternberg cell
  - A ***minority*** of cells in enlarged nodes (~1 to 5%)
- Release cytokines → generate **reactive cells**
  - Majority of cells in node are reactive
  - B symptoms common (more than non-Hodgkin lymphoma)
  - Macrophages may activate → hypercalcemia

25-OH Vitamin D $\xrightarrow{1\alpha \text{ - hydroxylase}}$ 1,25-OH_2 Vitamin D

Hodgkin Lymphoma

- Commonly presents with **cervical lymphadenopathy**
  - Often with B symptoms
- Spreads in a very predictable manner
- Limited disease highly curable
- **Stage** is strongest predictor of prognosis

Hodgkin Lymphoma

- **Bimodal** age distribution
  - Peaks at age 20 and 65
- Risk factors
  - Prior EBV infection (virus infects B cells)
  - Immunosuppression (HIV, transplant)
  - Autoimmune disease: Rheumatoid arthritis and lupus
- Treatment: chemotherapy and radiation

Classification



Lymphocyte Predominant

Nodular Lymphocyte Predominant

- Rare variant of Hodgkin lymphoma
- Malignant cell: LP cells
  - Lymphocyte predominant
  - Sometimes called "**popcorn cells**"
- Unusual surface marker expression
  - Usually lack CD15 and CD30
  - **Express CD20**

Popcorn Cells



Nephron/Wikipedia

Classical Hodgkin Lymphoma

- Nodular sclerosing
  - Most common type HL: 60% to 80% of all cases
  - More common in women (most HL more common men)
  - Often presents with a **mediastinal mass on CXR**
  - Reed-Sternberg cells seen in clear space ("lacunar variant")
  - Slow growing ("indolent")
  - Good long-term survival

Classical Hodgkin Lymphoma

- Mixed cellularity
  - Eosinophils, neutrophils, macrophages, plasma cells
- Lymphocyte rich
  - Excellent prognosis
- Lymphocyte depleted
  - Poor prognosis

Hodgkin versus. Non-Hodgkin

Clinical Features

Hodgkin

- Often localized
- Orderly spread from node to node
- Extranodal involvement rare

Non-Hodgkin

- Often multiple peripheral sites
- Noncontiguous spread
- Extranodal involvement common
  - GI (thickened bowel wall)
  - Skin

Hodgkin Lymphoma

Treatment

- Many different regimens
- ABVD
  - Adriamycin (doxorubicin) - cytotoxic antibiotics
  - Bleomycin - cytotoxic antibiotics
  - Vinblastine – microtubule inhibitor
  - Dacarbazine – alkylating agent

Non-Hodgkin Lymphoma

Jason Ryan, MD, MPH

Lymphomas

- Malignancies of lymphocytes (B cells, T cells)
- Often involve **lymph nodes**
- Also “extranodal” (skin, GI tract)



Wikipedia/Public Domain

Lymphomas



Hodgkin versus. Non-Hodgkin

Clinical Features

Hodgkin

- Often localized
- Orderly spread from node to node
- Extranodal involvement rare

Non-Hodgkin

- Often multiple peripheral sites
- Noncontiguous spread
- Extranodal involvement common
  - GI (thickened bowel wall)
  - Skin

Waldeyer's Ring

- Lymphoid tissue in the pharynx
- Often involved in **non-Hodgkin lymphoma**
  - Rare in Hodgkin lymphoma



Wikipiedia/Public Domain

Lymphocyte Antigens

Primarily T-Cell Associated	Primarily B-cell Associated
CD1 CD2 CD3 CD4 CD5 CD7 CD8	CD10 CD19 CD20 CD21 CD22 CD23

Non-Hodgkin Lymphoma

- B and T cell malignancies
  - Most are B cell disorders
  - Malignant cells obliterate lymph node architecture
- More than two dozen subtypes per WHO
- Classified by:
  - B versus T cell
  - Cell size (small versus large)
  - Histologic appearance
  - Expression of markers ("immunophenotype")
  - Genetics

Non-Hodgkin Lymphoma

- Follicular
- Marginal cell
- Mantle zone
- Diffuse Large B Cell
- Small lymphocytic lymphoma
- Burkitt's
- Adult T-cell Leukemia/Lymphoma
- Cutaneous T-cell Lymphomas

Lymph Nodes



Lymphoid Follicles



Gleiberg/Wikipedia

Diffuse Large B-cell Lymphoma

- **Most common NH lymphoma**
- B cell malignancy
  - Express CD19, CD20
  - Most cells express surface immunoglobulin

Diffuse Large B-cell Lymphoma



KGH/Wikipedia

Diffuse Large B-cell Lymphoma

- Median age at presentation is 64 years
- Occurs in HIV
  - AIDS defining malignancy

Diffuse Large B-cell Lymphoma

Prognosis

- Variable prognosis
- International Prognostic Index (IPI) score
  - Age >60 years
  - Increased LDH
  - Patient functional status
  - Clinical stage
  - Number of extranodal sites

Rituximab

- Monoclonal CD20 antibody
- Used in CD20+ B cell lymphomas
  - Diffuse large B cell
  - Follicular

Follicular Lymphoma



Patho/Wikipedia

Follicular Lymphoma

- B cell malignancy
  - Usually express CD19, CD20
  - Most cells express surface immunoglobulin

Follicular Lymphoma

- Genetic hallmark: **14;18 translocation**
- Overexpression of **BCL2**
  - Blocks apoptosis ("antagonist" of apoptosis)
  - Germinal center B cells usually lack BCL2
  - Undergo apoptosis unless selected by somatic hypermutation



Follicular Lymphoma

- Median age at diagnosis: **65 years**
- **Indolent course**: waxes/wanes for years
  - Not all patients require treatment
  - Difficult to cure
- Diffuse large B cell lymphoma (DLBCL)
  - Histologic transformation: 10 to 70% cases over time
  - Poor prognosis

Lymphoma vs. Reactive

- Follicular lymphoma vs. reactive lymphadenopathy
  - Both have ↑ follicle growth
  - Must distinguish in diagnosis of lymphoma
- Reactive lymphadenopathy (LAD)
  - Somatic hypermutation of B cells
  - Apoptosis of many B cells
  - B cell death → debris → macrophages

Lymphoma vs. Reactive

Lymphoma	Reactive LAD
Similar size/shape follicles	Varying size/shape follicles
Relative absence of macrophages	Tingible body (debris-laden) macrophages
++ BCL2 Staining	-- BCL2 Staining

Mantle Cell Lymphoma

- B cell malignancy
  - Follicle mantle or germinal center
  - Usually express CD19,CD20
  - Most cells express surface immunoglobulin
  - **Express CD5** ("Co-express CD20 and CD5")
- Median age at diagnosis: 68 years
- Median overall survival: 3 to 4 years (poor prognosis)

Mantle Cell Lymphoma

- 50 to 65%: **11;14 translocation**
- Overexpression of **cyclin D1**
  - Promotes cell cycle transition from G1 to S phase



Marginal Zone Lymphoma

- B cell malignancies
- Marginal zone forms from inflammation
- Often extranodal
- Lymphoma in **chronic inflammatory disorders**
  - Salivary glands in Sjogren's
  - Thyroid gland in Hashimoto's thyroiditis
  - Stomach in chronic H. Pylori infection (MALToma)

Small Lymphocytic Lymphoma

- CD5+ B cells
  - "Co-express CD20 and CD5"
  - Similar markers to mantle cell lymphoma
  - Typically negative for cyclin D1
- Same malignant cells as CLL
  - Only difference is degree of lymphocytosis (↑WBC)
  - Peripheral blood: normal or mild lymphocytosis
- SLL definition: lymphocyte count of <5000
  - If >5000 → CLL

Burkitt's Lymphoma

- B cell malignancy
  - Usually express CD19, CD20
  - Most cells express surface immunoglobulin
- Very aggressive – rapid proliferation
- Key distinctions:
  - "Starry sky" morphology
  - Epstein-Barr virus (EBV)
  - C-myc translocation

Burkitt's Lymphoma



Wikipedia/Public Domain

Burkitt's Lymphoma

- Endemic form
  - Found in Africa and New Guinea
  - 30 to 50% of childhood cancer in some regions
  - **Children** four to seven years old
  - Male to female ratio ~ 2:1
  - Commonly presents as mass in the **mandible**
- Sporadic form
  - Also occurs in children
  - **Abdominal mass**: ileocecum or peritoneum

Burkitt's Lymphoma



Mike Blyth/Wikipedia

Burkitt's Lymphoma

Associations

- Epstein Barr virus (EBV) infection
  - Nearly all endemic tumors associated with latent infection
  - Express CD21 (EBV receptor)

Burkitt's Lymphoma

Associations

- C-myc translocation
  - Growth promoter
  - Activates transcription



T-Cell Leukemia/Lymphoma

- CD4+ T cell malignancy
- Occurs with HTLV-1 infection
  - RNA Virus
  - Infects CD4+ T cells
- Key diagnostic test: anti-HTLV1 antibodies

T-Cell Leukemia/Lymphoma

- Clinical scenario
  - Patient from Japan, Caribbean, West Africa (endemic regions)
  - Lymphocytosis
  - Lymphadenopathy
  - Skin lesions (ulcers, nodules, papular rash)
  - Rapidly progressive symptoms → usually fatal in months
- Lytic bone lesions with ↑ calcium
  - Don't confuse with multiple myeloma

Cutaneous T-cell Lymphoma

CTCL

- Skin disorder of malignant T-cells
  - Variable expression of CD markers
- Presents with skin lesions
  - Localized disease: Mycosis Fungoides
  - Diffuse systemic disease: Sezary syndrome

Cutaneous T-cell Lymphoma

CTCL

- Mycosis Fungoides
  - Patches, plaques, tumors
  - Varying size/shape
  - Lesions progress slowly changing size/shape/appearance
  - “Indolent”: Slowly developing
  - Classically in a “bathing trunk” distribution
- Diagnosis: Skin biopsy shows lymphoid cells
  - Upper dermis
  - Epidermal aggregates (Pautrier microabscesses)

Cutaneous T-cell Lymphoma

CTCL

- Sezary syndrome
  - T-cell lymphoma affecting skin of entire body
  - Widespread erythema (skin bright red)
  - Lymphadenopathy
  - Malignant cells in blood (Sezary cells)



El*Falaf

Multi-lobed nucleus
"Cerebriform"

Plasma Cell Disorders

Jason Ryan, MD, MPH

Hematopoiesis



Mikael Häggström /Wikipedia

Multiple Myeloma

- Malignancy of plasma cells
  - Dependent on **IL-6**
  - Required for myeloma cell proliferation
- Excess production of **immunoglobulin**
- Disorder of older patients (median age: 66)

IL-6

Multiple Myeloma

- IgG (~50%)
- IgA (~20%)
- Light chains only (~15%)
- “Paraproteins”



Fvasconcellos /Wikipedia

IgG



IgA

Martin Brändli /Wikipedia

Light Chains

- Two types: Kappa (κ) or lambda (λ)
  - Each antibody: two identical light chains
  - Heavy chain type determines antibody type: G, A, E, etc.
- Slight excess of light chains produced normally
- Filtered by glomerulus → reabsorbed proximal tubule



Yohan/Wikipedia

Light Chains

- Excess light chains can occur in multiple myeloma
- Excess light chains leads to pathology:
  - Renal damage
  - AL amyloidosis



Yohan/Wikipedia

SPEP

Serum protein electrophoresis

- Electrical current separates serum proteins
  - Based on size and charge
- Gamma fraction contains immunoglobulin
- Multiple myeloma: "**M spike**"



Normal SPEP



Multiple Myeloma

Multiple Myeloma

Clinical Features

- Bone pain/fractures
- Hypercalcemia
- Renal failure
- Anemia
- Infections

Multiple Myeloma

Bone/hypercalcemia

- **Osteoclast-mediated** bone resorption
- Caused by **cytokines** from myeloma cells
- "Lytic lesions" on x-ray ("punched out")
- Pathologic fractures, especially vertebral column
- Elevated serum **calcium**



Utsav Agrawal

Multiple Myeloma

Renal Failure

- Caused by **light chains** and **hypercalcemia**
- Light chains ("myeloma kidney")
  - Small amount of light chains normally filtered/reabsorbed
  - MM: proximal tubular capacity exceeded
  - Light chains reach distal tubule
  - Combine with Tamm–Horsfall mucoprotein (THP)
  - Form obstructing **casts**
  - Light chains in urine = "Bence Jones" proteins

Multiple Myeloma

Renal Failure

- **Hypercalcemia**
  - Impairs renal ability to concentrate urine
  - Polyuria → volume contraction
  - Decreased GFR

Multiple Myeloma

Renal Failure

J3D3

- Urine dipstick negative for protein
  - Mostly detects albumin
  - Poor detection of light chains
- **Urine protein electrophoresis (UPEP)**
  - Similar to SPEP ("SPEP/UPEP")
  - Detects light chains ("Bence Jones proteins")

Multiple Myeloma

Renal Failure

- Serum free light chain
  - Antibody-based system
  - Sensitive test for ***serum*** kappa/lambda light chains
  - Alternative to UPEP

Multiple Myeloma

Anemia

- Normocytic, normochromic
- Multifactorial
  - Bone marrow replacement by plasma cells
  - Renal failure (low EPO)
- Weakness, pallor often present at diagnosis

Multiple Myeloma

Infections

- Infection is leading cause of death
- Decreased production of normal immunoglobulins
  - Depressed humoral immunity
- Recurrent **bacterial** infections
  - Strep Pneumoniae
  - Staph Aureus
  - E. Coli

Rouleaux

- RBCs form a stack of coins
- Caused by elevated protein levels in plasma



Gabriel Caponetti /Wikipedia

Multiple Myeloma

Diagnosis

- SPEP: Monoclonal protein
- Diagnostic criteria
  - Bone marrow biopsy: clonal bone marrow plasma cells
  - End-organ damage

MGUS

Monoclonal gammopathy of undetermined significance

- Asymptomatic plasma cell disorder
- Abnormal SPEP (presence of M protein)
- No end-organ damage
- Can progress to multiple myeloma
- Often detected in workup of another problem
  - Anemia
  - Hypercalcemia
  - Bone pain

Waldenstrom Macroglobulinemia

- Also called lymphoplasmacytic lymphoma
- **B-cell lymphoma**
- Tumor cells differentiate into plasma cells
- Produce **IgM antibodies**
- Leads to hyperviscosity symptoms



Martin Brändli /Wikipedia

Waldenstrom Macroglobulinemia

- Weakness, fatigue, weight loss
- Lymphadenopathy (25% of patients)
  - Sometimes splenomegaly, hepatomegaly
- **No osteolytic bone lesions**
- SPEP: M spike from IgM



Steven Fruitsmaak

Hyperviscosity Syndrome

- IgM increases viscosity of blood
- Sluggish blood flow and sludging
- **CNS**: Headache, dizziness, coma
- **Visual impairment**
- Medical emergency: emergent plasmapheresis

Poiseuille's Law

$$R = \frac{8\,\eta\,(\text{viscosity})\,L\,(\text{length})}{\Pi\,r\,(\text{radius})^{4}}$$

Amyloidosis

Jason Ryan, MD, MPH

Amyloid

- Amyloid: Pathologic aggregate of amyloid proteins
- "Pathologic:" Damages tissues
- Accumulates in **extracellular** space of tissues
- Amyloid proteins:
  - More than 20 proteins form amyloid
  - Different proteins = different diseases

Amyloid

- Localized amyloid deposition
  - Alzheimer's: Beta Amyloid
  - Cerebral amyloid angiopathy: Beta Amyloid
  - Type II diabetes: Amylin deposits in pancreas
- Diffuse amyloid deposition = **amyloidosis**

Systemic Amyloidosis

- Primary (AL) amyloidosis: Light chains
- Secondary (AA) amyloidosis: Serum amyloid A
- Dialysis-related amyloidosis: Beta-2 microglobulin
- Age-related systemic amyloidosis: : Transthyretin
- Familial
  - Many types
  - Most common: Abnormal transthyretin gene

Transthyretin

- Formerly called prealbumin
- Transports thyroid hormone and retinol (vitamin A)
- Amyloidosis: Amyloid transthyretin (ATTR)
- Mutant form seen in **hereditary** amyloidosis
- Normal transthyretin seen in **age-related** amyloidosis

Amyloid

- Pink on standard biopsy
  - Similar to collagen, fibrin, other proteins
- Specialized stain for detection
  - Congo red
  - Pink under ordinary light
  - Shows apple-green birefringence under polarized light



Ed Uthman, MD

Amyloid

- Forms **beta-pleated sheets**
  - Secondary protein structure
  - Detected by crystallography and spectroscopy
- Responsible for Congo Red staining



Dcrjsr

AL Amyloidosis

Primary Amyloidosis

- Plasma cell malignancy ("dyscrasia")
  - Amyloid formed from **light chains**
  - Can occur alone
  - Also in association with MM, Waldenstrom's, lymphoma
- Bone marrow biopsy: monoclonal plasma cells
- Can be treated with stem cell transplantation

AA Amyloidosis

Secondary Amyloidosis

- Occurs in chronic inflammatory conditions
- Rheumatoid arthritis, ankylosing spondylitis, IBD
- Amyloid: **serum amyloid A (SAA) proteins**
  - SAA proteins: acute phase reactants
  - Apolipoproteins
  - Many roles in inflammatory response

Familial Mediterranean Fever

Neutrophil

Mikael Häggström

- Rare hereditary disorder
- Inflammatory disease
- Involves neutrophils
- Recurrent episodes of fever and inflammatory pain
- "Serosal" inflammation
  - Abdominal pain; pericarditis
- Secondary (AA) amyloidosis: **major cause of death**
- Treatment: **Colchicine** (inhibits neutrohpils)

Dialysis-related Amyloidosis

- **β2 microglobulin**
- Complication of renal failure
- Dialysis does not effectively remove β2 microglobulin
- Bones, joints, tendons
- **Shoulder pain**
- **Carpal tunnel syndrome**



atropos235

Age-related Amyloidosis

Senile Amyloidosis

- **Wild-type (normal) transthyretin**
- Usually develops >70 years old
- Predominantly occurs in the heart
- Rarely other significant organ involvement

Familial Amyloidosis

- **Mutant transthyretin**
- Produced by **liver**
- Can be treated with liver transplant
- Symptoms in adulthood



Wikipedia/Public Domain

Amyloidosis

Clinical Features

- May involve almost any tissue/organ
- Skin: Periorbital purpura (raccoon eyes)
- Muscles: Enlarged tongue
- Nerves: Peripheral neuropathy
- Liver: Hepatomegaly
- Bowel: Malabsorption
- Blood vessels: Bleeding



Professor P N Hawkins

Amyloidosis

Clinical Features

- Kidneys
  - Most commonly involved organ
  - Leads to proteinuria and the **nephrotic syndrome**



Image courtesy of BruceBlaus

Amyloidosis

Clinical Features

- Heart
  - Can cause a **restrictive** cardiomyopathy
  - Common with light chains and transthyretin amyloidosis
  - Increased wall thickness, diastolic heart failure
  - **Arrhythmias**, sudden death





Amyloidosis

Diagnosis

- Biopsy: tissue infiltration of amyloid
- **Abdominal fat pad** preferred
  - Easy to access (low risk procedure)
  - Good sensitivity



Wikipedia/Public Domain

Amyloidosis



Myeloproliferative Disorders

Jason Ryan, MD, MPH

Myeloproliferative Disorders

- Disorders of myeloid **proliferation**
  - Granulocytes, red cells, platelets
- Often leads to increased peripheral cell counts
  - Chronic myeloid leukemia: granulocytes
  - Essential thrombocytosis: platelets
  - Polycythemia vera: red blood cells

Myeloproliferative Disorders

Major Types

- Chronic myeloid leukemia (granulocytes)
- Essential thrombocytosis (platelets)
- Polycythemia vera (red blood cells)
- Myelofibrosis

Myeloproliferative Disorders

Major Types

- Chronic myeloid leukemia (granulocytes)
- Essential thrombocytosis (platelets)
- Polycythemia vera (red blood cells)
- Myelofibrosis

Myeloproliferative Disorders

Major Types

Disorder	Genetics
Chronic Myelogenous Leukemia	Philadelphia Chromosome t 9;22; BCR-ABL
Polycythemia Vera	JAK2 (~100%)
Essential Thrombocytosis	JAK2 (~60%)
Myelofibrosis	JAK2 (~60%)

JAK2 Mutation

- Gene for cytoplasmic **tyrosine kinase**
  - Chromosome 9
- Mutation → ↑ tyrosine phosphorylation
- Progenitor cells: **Hypersensitivity to cytokines**
- More growth; longer survival

Polycythemia Vera

- Elevated red blood cell mass

Measurement	Normal	P. Vera
Hgb (g/dL)	15	20
Hct (%)	45	60

Polycythemia Vera

- Must exclude other causes
  - Hypoxia (lung disease)
  - EPO secreting tumor (renal cell carcinoma)

Measurement	Hypoxia	RCC	P. Vera
PaO_2	↓	Normal	Normal
EPO	↑	↑	↓

Polycythemia Vera

Symptom Mechanisms

- Increased **RBC mass**
  - Leads to increase in **blood volume**
  - Causes hypertension, flushing
- Thrombosis
  - Increased viscosity of blood
  - Also increased platelets

Poiseuille's Law

$$R = \frac{8\,\eta\,(\text{viscosity})\;L\,(\text{length})}{\Pi\;r\,(\text{radius})^{4}}$$

Polycythemia Vera

Symptoms

- Many patients asymptomatic (routine CBC)
- Red, puffy skin ("facial plethora")
- **Aquagenic pruritus**
  - "Unbearable" pruritus after warm bath or shower
- **Deep vein thrombosis**
  - Classically Budd Chiari syndrome (hepatic vein)

Polycythemia Vera

Treatment

- Phlebotomy
- Hydroxyurea
  - Inhibits **ribonucleotide reductase**
  - Blocks formation of deoxynucleotides for DNA



Public Domain

Polycythemia Vera

Complications

- Spent phase (~15% of patients)
  - Progression to **myelofibrosis**
- **Leukemia**
  - Usually acute myeloid leukemia (AML)
  - Rarely chronic myeloid leukemia (CML)
- **Gout**
  - Excess DNA turnover from ↑ RBC production
  - Increased **purine** metabolism → ↑ uric acid
  - Also seen in CML

Essential thrombocytosis

Essential thrombocythemia

- Malignant proliferation of myeloid cells
- Predominantly affects **megakaryocytes/platelets**

Essential thrombocytosis

Essential thrombocythemia

- "Diagnosis of exclusion"
- Must exclude a **reactive thrombocytosis**
  - Iron deficiency anemia
  - Acute bleeding or hemolysis
  - Infections/inflammation
  - Metastatic cancer
- Key blood test: acute phase reactants
  - C-reactive protein, fibrinogen, ESR, ferritin
  - Increased levels suggest occult inflammatory process

Essential thrombocytosis

Symptoms

- Abnormal platelet function
- **Bleeding**
- **Thrombosis**

Essential thrombocytosis

Prognosis and Treatment

- Most patients have no disease-related complications
- Polycythemia vera complications unusual
  - AML, myelofibrosis, hyperuricemia
- High risk patients treated with:
  - Hydroxyurea
  - Aspirin

Myelofibrosis

- Primary myelofibrosis
  - Myeloproliferative disorder
- Secondary myelofibrosis
  - Polycythemia vera, chronic leukemia, other causes

Primary Myelofibrosis

- Excess collagen from fibroblasts → marrow fibrosis
- Stimulation by growth factors of **megakaryocytes**
  - Platelet-derived growth factor (PDGF)
  - Transforming growth factor beta (TGF-B)



Primary Myelofibrosis

Pathophysiology

- Marrow failure → **extramedullary hematopoiesis**
- Spleen, liver, lymph nodes
- Can be seen in CNS, lungs, bladder, even in skin!

Primary Myelofibrosis

Clinical Features

- Occurs in older patients (median age 67)
- Fatigue, weight loss, night sweats
  - Increased metabolism

Primary Myelofibrosis

Clinical Features

- Massive splenomegaly
  - Spleen: principle site of **extramedullary hematopoiesis**
  - Left upper abdominal pain
  - Early satiety (compression of stomach)
- May also see enlarged liver, lymph nodes
- Leukoerythroblastosis
  - Inappropriate release of cells from marrow
  - Immature erythroid and granulocyte precursors in blood

Primary Myelofibrosis

Clinical Features

- Normocytic, normochromic anemia
  - Severe
  - Hemoglobin often less than 10g/dL
- WBC and platelets variable
  - Elevated, normal, or reduced
  - Immature neutrophils seen
  - Myeloblasts
- Hyperuricemia (gout)
  - High cell turnover → increased metabolism
- Treatment: Stem cell transplant

Tear Drop Cells

Dacrocytes

- Classic finding of myelofibrosis
- Red blood cells deformed leaving fibrotic marrow



Paulo Henrique Orlandi Mourao/Wikipedia

Langerhans Cell Histiocytosis

- Histiocyte = connective tissue macrophage
- Histiocytosis = proliferation of histiocytes
- Langerhans Cell = dendritic cells
  - Common in skin, connective tissue
  - Consume antigens
  - Migrate to lymph nodes
  - Present antigens → activate T-cells

Langerhans Cell Histiocytosis

- Clonal proliferation of dendritic cells
- Cells of myeloid origin
- Express CD1a, S100, CD207
  - Same as Langerhans cells

Birbeck Granules

- Found in cytoplasm of Langerhans cells
- Seen on electron microscopy



Yale Rose/Wikipedia

Langerhans Cell Histiocytosis

Clinical Features

- Most common in **children**
- Can involve any organ system
- Often involves **bone** and **skin**

Langerhans Cell Histiocytosis

Clinical Features

Letterer-Siwe Disease
Occurs in child (~2 years old)
Diffuse skin rash
Cystic bone lesions
Multi-system failure
Rapidly fatal

↔ Spectrum

Eosinophilic Granuloma
Adolescents
No skin involvement
Pathologic bone fracture
NOT osteosarcoma
Langerhans cells/eosinophils

Hand-Schuller-Christian Disease
Triad: skull, diabetes insipidus, exophthalmos
Scalp lesion
Posterior pituitary (DI)
Protrusion of eye

Langerhans Cell Histiocytosis

Clinical Features



Countincr/Wikipedia



Madhero88/Wikipedia

Antimetabolites

Jason Ryan, MD, MPH

Antimetabolites

- Chemotherapy drugs used to treat malignancy
- **Block formation of components of DNA**
- Cell cycle specific
- Toxic effects in **S phase** of cell cycle

Antimetabolites

- Cytarabine
- Cladribine
- Methotrexate
- 5-fluorouracil
- Azathioprine
- 6-mercaptopurine
- 6-thioguanine
- Hydroxyurea

Nitrogenous Bases

Pyrimidines



Cytosine



Thymine



Uracil

Purines



Adenine



Guanine

Nucleotides

Pyrimidines



Cytidine



Thymidine



Uridine

Purines



Adenosine



Guanosine

Deoxyribonucleotides



ADP

Ribonucleotide Reductase



dADP



GDP



dGDP

Common Side Effects

- Drugs target rapidly dividing cells (DNA synthesis)
- Bone marrow precursors cells: rapidly dividing
- **Myelosuppression**
  - Megaloblastic anemia
  - Thrombocytopenia
  - Leukopenia
- Absolute neutrophil count (ANC)
  - Less than 500 cells/μL = neutropenia
  - High risk of infections

Megaloblastic Anemia

- Anemia (↓Hct)
- Large RBCs (↑MCV)
- Hypersegmented neutrophils
- Commonly caused by defective DNA production
  - B12/Folate deficiency
  - Chemotherapy drugs (MTX, 5-FU, hydroxyurea)



Wikipedia/Public Domain

Cytarabine

Ara-C or cytosine arabinoside

- **Pyrimidine** analog
- Mimics cytidine
- Inhibits DNA polymerase



Ara-C



dCytidine

Cytarabine

Ara-C or cytosine arabinoside

- Only effective in leukemia and lymphomas
- Adverse effects
  - Myelosuppression
  - Nausea/vomiting
  - High doses: Neurotoxicity
  - Peripheral neuropathy, confusion, cerebellar ataxia

Cladribine

- **Purine** analog
- Mimics adenosine
- Highly toxic to lymphocytes
- Drug of choice in **hairy cell leukemia**
- Main adverse effect is myelosuppression



Adenosine



Cladribine

Methotrexate

- Mimics of folate
- Inhibits **dihydrofolate reductase**
- Blocks synthesis if **tetrahydrofolate**
- Required for DNA, RNA, some proteins
- Blocks synthesis **thymidine** (dTMP)



Folate



Methotrexate

Thymidine



dUridine-MP

Thymidylate Synthase



Thymidine-MP

N5, N10 Tetrahydrofolate

DHF ← Folate

THF

Dihydrofolate Reductase

Methotrexate

Clinical Uses

- Oral or intravenous
- Many malignancies
  - Solid tumors
  - Leukemia/Lymphomas
- Immunosuppression
  - Autoimmune diseases
  - “Steroid sparing” agents
  - Used to wean/eliminate need for long-term steroid use
- Pregnancy abortion
  - Ectopic/tubal pregnancies

Methotrexate

Side Effects

- Myelosuppression
  - More common with high doses
  - Reversible with **leucovorin (folinic acid)**
  - Converted to THF
  - Does not require dihydrofolate reductase
  - “Leucovorin rescue”

Methotrexate

Side Effects

- Mucositis (mouth soreness)
  - Occurs with many chemo agents
  - Common with methotrexate
  - GI epithelial cell damage
  - Loss of mucosal integrity → pain, bacterial growth
- Abnormal LFTs, GI upset

Methotrexate

Side Effects

- Rarely causes **methotrexate-induced lung injury**
  - Often after week/months of low-dose therapy
  - Usually a hypersensitivity reaction
  - Lymphocytes, eosinophils
  - Can progress to pulmonary fibrosis
  - Usually resolves on discontinuation of drug



5-Fluorouracil

5-FU



Fluorouracil



Uracil

- Mimics **uracil** (**pyrimidine**)
- Converted to 5-FdUMP (abnormal dUMP)
- Inhibition thymidylate synthase
- Blocks dTMP synthesis ("thymineless death")
- Effects ***enhanced*** by leucovorin

5-Fluorouracil

5-FU



Fluorouracil

- Commonly used in **colorectal cancer**
- Other solid tumors: breast, pancreas
- Topical therapy for basal cell skin cancer
- Adverse effects
  - Myelosuppression
  - Nausea/vomiting/diarrhea
  - Mucositis
  - Cerebellar ataxia and encephalopathy (rare)
  - Coronary vasospasm

6-Mercaptopurine

- Mimics hypoxanthine/guanine (**purines**)
- Added to PRPP by HGPRT → Thioinosinic acid
- Inhibits multiple steps in purine salvage
- ↓IMP/AMP/GMP



Hypoxanthine



6-MP



Guanine

6-Mercaptopurine



6-MP



Guanine



Hypoxanthine

GMP

AMP





PRPP

HGPRT

Hypoxanthine-Guanine phosphoribosyltransferase

Inosine monophosphate (IMP)

Purine Salvage Pathway

Azathioprine

- Pro-drug
- Converted by the body to 6-MP



Azathioprine 6-MP

Azathioprine/6-MP

Clinical Uses

- Immunosuppression
  - Steroid sparing agents
  - Inflammatory bowel disease
  - Solid organ transplant
  - Autoimmune diseases

Azathioprine/6-MP

Adverse Effects

- Myelosuppression
- Abnormal LFTs
- Anorexia/nausea/vomiting

Xanthine Oxidase

- Purine metabolism enzyme
- Converts xanthine into uric acid
- Inhibited by allopurinol and febuxostat (gout)



Azathioprine/6-MP

- Also metabolized by xanthine oxidase
- Converts 6-MP to inactive metabolite
- Caution with allopurinol/febuxostat



Azathioprine

6-MP

6-thiouric acid
(inactive)

6-Thioguanine

- Also mimics hypoxanthine/guanine (**purines**)
- Similar mechanism to 6-MP
- ↓IMP/AMP/GMP



Guanine



6-TG

Hydroxyurea

- Inhibits **ribonucleotide reductase**
- Blocks formation of deoxynucleotides
- Good oral bioavailability – can be used PO
- Main adverse effect is myelosuppression



Hydroxyurea

- Rarely used for malignancy
- Used for polycythemia vera, essential thrombocytosis
- Used in sickle cell anemia
  - Increases fetal hemoglobin levels (mechanism unclear)



Antimetabolites





Folate	Purines	Pyrimidines	Other
Methotrexate	Cladribine 6-MP Azathioprine 6-TG	Cytarabine 5-FU	Hydroxyurea

Alkylating Agents

Jason Ryan, MD, MPH

Alkyl Groups

- Molecular groups with formula: C_nH_{2n+1}
- Methyl group: $-CH_3$
- Ethyl group: $-CH_2CH_3$
- Propyl group: $-CH_2CH_2CH_3$

Alkylating Agents

- Add alkyl groups to nucleotide bases
- Most commonly **N7 nitrogen of guanine**
- **DNA strands cross link**
- Inhibit DNA replication and cause DNA damage
- Cell cycle non-specific



Guanine

Alkylating Agents



Guanine



Guanosine



N7 interstrand crosslinked DNA

Alkylating Agents

- Nitrogen mustards
- Nitrosoureas
- Busulfan
- Dacarbazine

Nitrogen Mustards

Alkylating Agents

- Alkylating agents similar to mustard gas
- Contain nitrogen and two chlorine atoms



Nitrogen Mustards

Alkylating Agents



Mechlorethamine



Cyclophosphamide



Melphalan



Chlorambucil



Ifosfamide

Cyclophosphamide

- Intravenous or oral forms
  - Good bioavailability when given orally
- Powerful immunosuppressant
  - Used in vasculitis, glomerulonephritis (oral)
- Solid tumors, lymphomas, leukemia



Cyclophosphamide

Cyclophosphamide

- Prodrug: Requires bioactivation by **liver**
  - Converted to **phosphoramide mustard**
  - Metabolized by **liver P450 system**



Wikipedia/Public Domain

Cyclophosphamide



Cyclophosphamide

Liver P450



4-Hydroxy cyclophosphamide

Tissues

Aldophosphamide

Acrolein



Phosphoramide Mustard (Cytotoxic)



Cyclophosphamide

Side Effects



Mesna

- Myelosuppression
  - ↓WBC, ↓Hct, ↓Plt
- Hemorrhagic cystitis
  - **Acrolein** metabolite toxic to bladder
  - Hematuria +/- dysuria
  - Lower risk with hydration and **mesna**
  - Mesna: sodium 2-mercaptoethane sulfonate
  - Mesna binds and inactivates acrolein in the urine

Cyclophosphamide

Side Effects



Holly Fischer/Wikipedia

- SIADH
  - Drug has antidiuretic affects
  - Usually occurs with IV dosing for chemotherapy
  - **Hyponatremia**; possible **seizures**
  - Compounded by IVF
  - Complex mechanism: More ADH release, less renal response

Ifosfamide



Ifosfamide

- Isomer of cyclophosphamide
- Used in germ cell cancer and sarcomas
- May also cause **hemorrhagic cystitis**

Ifosfamide



Ifosfamide

- Special side effect: **nephrotoxicity**
  - Toxic to proximal tubular cells
  - May cause **Fanconi syndrome**
  - Polyuria
  - Electrolyte losses: Hypokalemia, hypophosphatemia
  - Metabolic acidosis (loss of bicarb in urine)
- Special side effect: **encephalopathy**
  - 10-30% of patients

Nitrosoureas



Carmustine
bis-chloroethylnitrosourea
BCNU



Lomustine
chloroethylnitrosourea
CCNU



Streptozotocin



Semustine

Nitrosoureas

- Bioactivated in **liver**
- Highly lipid soluble → cross blood-brain barrier
- Used for **brain tumors** (glioblastoma multiforme)



Wikipedia/Public Domain

Nitrosoureas

Toxicity

- Myelosuppression
- Rarely leads to **pulmonary fibrosis**
- Rarely chronic interstitial nephritis (renal failure)
- **Encephalopathy and seizures**
  - Very high dosages (BCNU for bone marrow transplant)

Busulfan



- **Myeloablation**
  - Single, high-dose of Busulfan
  - Results in severe pancytopenia (bone marrow ablation)
  - Preparation for stem cell transplant
- Chronic myeloid leukemia (CML)

Busulfan

Toxicity

- Myelosuppression
- Skin hyperpigmentation
  - Also occurs with other chemotherapy (Bleomycin)
- Seizures (high dosages)

Busulfan

Toxicity

- **Pulmonary toxicity**
  - Cough, dyspnea
  - Can progress to pulmonary fibrosis
  - Ground glass opacities
  - Restrictive PFTs
  - Reduced DLCO



Dacarbazine

- Part of ABVD protocol for Hodgkin lymphoma
  - Adriamycin (doxorubicin) - cytotoxic antibiotics
  - Bleomycin - cytotoxic antibiotics
  - Vinblastine – microtubule inhibitor
  - **Dacarbazine** – alkylating agent



Procarbazine

- Part of MOPP protocol for Hodgkin lymphoma
  - Mechlorethamine – Mustard agent
  - Oncovin (Vincristine) – Microtubule drug
  - **Procarbazine**
  - Prednisone



Antitumor Antibiotics

Jason Ryan, MD, MPH

Antitumor Antibiotics

- Drugs derived from *Streptomyces* bacterial strains
- Anthracyclines
- Dactinomycin
- Bleomycin

Anthracyclines

- Key drugs: daunorubicin and doxorubicin
- Others: idarubicin, epirubicin, mitoxantrone



Daunorubicin



Doxorubicin
(Adriamycin)

Anthracyclines

- Multiple toxic mechanisms
  - Inhibition of topoisomerase II → DNA breaks
  - Intercalation of DNA → blocks synthesis of DNA/RNA
  - Generation of free radicals
- Cell cycle non-specific

Topoisomerase II

- Cuts both strands of DNA helix then reseals
- Relieves tangles and supercoils
- Anthracycline inhibition → breaks with no resealing
- Result: DNA damage



DNA Intercalation

- Binds to DNA
- Inserts between base pairs
- Inhibits replication/transcription



Wikipedia/Public Domain

Free Radicals



Anthracyclines

Clinical Uses

- **Doxorubicin (Adriamycin)**
  - Widely used anticancer drug
  - **Breast cancer**
  - Many solid tumors
  - Childhood cancers: neuroblastoma, Ewing's, osteosarcoma
  - Leukemia/lymphoma

Anthracyclines

Cardiotoxicity

- **Systolic heart failure (↓LVEF)**
- **Free radical damage** to myocytes → necrosis
- Can present with dyspnea, fatigue, edema
- Screening: echocardiogram after infusions



Anthracyclines

Cardiotoxicity

- Rarely seen with lower total dosages
- **Dexrazoxane**
  - Iron chelating agent
  - Limits anthracycline-induced cardiotoxicity

Dactinomycin

Actinomycin D

- Several mechanisms
  - Intercalates in DNA
  - Inhibits RNA synthesis (transcription)
  - Double strand breaks
- **Childhood cancers**
  - Neuroblastoma, Ewing's sarcoma, osteosarcoma
- Major adverse effect: myelosuppression

Bleomycin

- Binds to DNA
- **Free radical formation** (oxygen, iron)
- Single and double strand breaks
- Cell cycle-specific drug: accumulates in **G2 phase**



Zephyris /Wikipedia

Bleomycin

Clinical Uses

- Lymphomas
- Germ cell tumors
- Head and neck cancer
- Squamous cell cancer of skin
- Cancers of cervix and vulva

Bleomycin

Toxicity

- Inactivated by enzyme bleomycin hydrolase
- Lower enzyme activity in skin and lungs
- **Skin toxicity**
  - Many skin changes described
  - Also seen with other chemotherapy drugs (Busulfan)
  - “Flagellate erythema”: Red/dark streaks on skin

Bleomycin

Pulmonary Toxicity

- Dose-limiting adverse effect
- Usually presents as **pneumonitis**
  - Cough, dyspnea, crackles
  - Infiltrates on chest X-ray
- Risk factors
  - Older patients (>70)
  - Prior pulmonary disease



Microtubule Inhibitors

Jason Ryan, MD, MPH

Microtubules

- Polymers of **α and β tubulin**
- Can grow/collapse
- Flagella, cilia, cellular transport (axons)



Thomas Splettstoesser (www.scistyle.com)

Mitosis

- Part of cell cycle
- Separation of chromosomes for cell division
- Depends heavily on **microtubules** (mitotic spindle)
- Followed by cytokinesis: cell divides



Lordjuppiter /Wikipedia

Mitosis

Metaphase

- Chromosomes line up on metaphase plate



Ali Zifan/Wikipedia

Mitosis

Anaphase

- Chromosomes separate



Ali Zifan/Wikipedia

Cell Cycle



Zephyris /Wikipedia

Microtubule Inhibitors

- Taxols
- Vinca alkaloids

Vocabulary

- Alkaloids
  - Naturally occurring substances
  - Nitrogen-containing bases
  - Usually derived from plants or trees



Nicotine
(Tobacco)



Morphine
(Opium)

Taxols

Paclitaxel, Docetaxel

- Alkaloids from yew trees
- Mitotic spindle poisons
- Bind microtubules
- **Enhance tubulin polymerization**
- Microtubules **cannot break down**
- Blocks cell cycle at metaphase/anaphase transition
- Anaphase cannot occur

Taxols

Clinical Use

- Solid tumors
  - Ovarian and breast cancer
  - Non-small cell and small cell lung cancer
  - Head and neck cancers
  - Prostate and bladder cancer

Taxols

Toxicity

- **Hypersensitivity** reactions (up to 30% patients)
  - Dyspnea/wheezing
  - Urticaria
  - Hypotension
- **Premedication** often used for prevention
  - Glucocorticoids and antihistamines
- **Nabpaclitaxel** (Abraxane)
  - Albumin-bound paclitaxel
  - Lower risk hypersensitivity reactions
  - Premedication not required



James Heilman, MD

Taxols

Toxicity

- Myelosuppression
- **Neuropathy**
  - Sensory nerves
  - Usually burning paresthesias of hands/feet

Vinca Alkaloids

Vincristine, vinblastine

- Derived from periwinkle plant (*Vinca rosea*)
- Bind **β-tubulin**
- **Inhibit polymerization**
- Prevent spindle formation
- Mitotic arrest in metaphase

Vinca Alkaloids

Clinical Uses

- Breast cancer
- Germ cell cancer
- Lymphomas
- ABVD Protocol (Hodgkin lymphoma)
  - Adriamycin (doxorubicin) - cytotoxic antibiotics
  - Bleomycin - cytotoxic antibiotics
  - **Vinblastine**
  - Dacarbazine – alkylating agent

Vinca Alkaloids

Toxicity

- Myelosuppression
- SIADH (rare)
- Vincristine: **Neurotoxicity**
  - Dose-limiting toxicity
  - Loss of axonal transport
  - Sensory and motor
  - Paresthesias/pain in fingers and feet
  - Distal weakness

DNA Drugs

Jason Ryan, MD, MPH

DNA Drugs

- Antitumor Antibiotics
- Alkylating agents
- Platinum agents
- Topoisomerase I and II inhibitors

Platinum Agents

Cisplatin, carboplatin, oxaliplatin

- Cross link DNA similar to alkylating agents
  - Most commonly at **N7 nitrogen of guanine**
  - "Alkylating like" drugs
  - Cell cycle nonspecific (like alkylating agents)



Cisplatin

Platinum Agents

Clinical Uses

- Solid tumors
  - Non-small cell and small cell lung cancer
  - Esophageal and gastric cancer
  - Head and neck cancers
  - Testicular cancer
  - Ovarian cancer

Platinum Agents

Toxicity

- All can cause **neuropathy**
  - Usually a peripheral sensory neuropathy
  - Pain, burning, tingling
  - Often in feet or hands
- May also cause **ototoxicity** (hearing loss)
- GI distress (nausea/vomiting) up to 90% patients



Pixabay/Public Domain

Platinum Agents

Nephrotoxicity

- Main, dose-limiting side effect of **cisplatin**
  - Often presents as acute kidney injury (↑BUN/Cr)
  - Prevented with IV fluids (normal saline)
  - Increase urine output (cause diuresis)
  - **Amifostine**: Free radical scavenger
  - Used in ovarian cancer with repeated cisplatin doses
- Carboplatin: less renal toxicity



Amifostine

Topoisomerases

- Relieve tangles and supercoils in DNA
- Cuts strands of DNA helix then reseal
- Chemotherapy inhibition → breaks with no resealing
- Result: DNA damage
- Affect S/G2 phase (during/after DNA synthesis)



Topoisomerases

- Topoisomerase I
  - Breaks single strands of DNA then reseals
- Topoisomerase II
  - Breaks double strands of DNA then reseals

Topoisomerase I Inhibitors

Irinotecan, topotecan

- "Camptothecins"
- From Camptotheca ("happy tree") tree in China

Geographer/Wikipedia

Topoisomerase I Inhibitors

Clinical Uses

- Irinotecan
  - Colon Cancer
- Topotecan
  - Ovarian cancer
  - Small cell lung cancer

Topoisomerase I Inhibitors

Toxicity

- Myelosuppression
- Severe diarrhea
  - Risk of volume depletion

Elya/Wikipedia

Topoisomerase II Inhibitors

Etoposide, teniposide

- Synthesized from Podophyllotoxins
- Derived from May apple plant (*Podophyllum)*

Wikipedia/Public Domain

Topoisomerase II Inhibitors

Clinical Use

- Intravenous and oral
- Germ cell cancers
- Small cell and non-small cell lung cancer
- Lymphomas
- Main toxicity: Myelosuppression, nausea/vomiting

Other Cancer Drugs

Jason Ryan, MD, MPH

Monoclonal Antibodies

- Laboratory-produced antibody
- Derived from cloned cells in culture
- Designed to bind a specific antigen
- Administered by intravenous infusion



Martin Brändli /Wikipedia

Infusion Reactions

- Usually occur after 1st or 2nd infusion
- Antibody-antigen binding → cytokine release
- Most are mild to moderate
- Fever/chills
- Flushing and itching
- Skin rashes
- Nausea, vomiting, and/or diarrhea
- Treatment/prevention: antihistamines, steroids

Bevacizumab

Avastin

- Monoclonal antibody to **VEGF-A**
- Prevents VEGF-A from binding VEGF receptors
- Used in many solid tumors
  - Colorectal cancer
  - Breast
  - Renal cell carcinoma

VEGF

Vascular endothelial growth factor

- Family of signal proteins
- Several forms (VEGF-A/B/C/D)
- VEGF-A: Stimulates **angiogenesis**
- Secreted by tumors → vascular growth
- VEGF Inhibitors
  - Bevacizumab (cancer)
  - Ranibizumab (retinopathy)

Bevacizumab

Toxicity

- VEGF mediates **vasodilation** via **nitric oxide**
- Inhibition → vasoconstriction
- **Cardiovascular** adverse effects
  - Hypertension
  - Increased risk of arterial thromboembolism
  - Myocardial infarction/stroke/TIA
- Other effects
  - Delayed wound healing
  - Bleeding

EGF

Epidermal growth factor

- Stimulates cell growth and differentiation
- Binds to **EGFR**
  - Tyrosine kinase receptor
  - EGF-EGFR binding → phosphorylation of tyrosine residues
  - Phosphorylated EGFR → downstream effects
- EGFR overexpressed in many tumors



Tyrosine

EGFR



Wikipedia/Public Domain

Cetuximab

- Monoclonal antibody
- Binds **extracellular domain** of EGFR
- Blocks binding of EGF-EGFR
- Solid tumors
  - Non-small cell lung cancer
  - Colon cancer
  - Head and neck cancer
- Side effects in clinical trial:
  - Rash (acne)
  - Diarrhea

Martin Brändli /Wikipedia

KRAS Mutation

Colorectal Cancer

- K-ras
  - G-protein
  - Downstream of EGFR
  - Can acquire activating mutations in colon cancer
  - Mutations isolate tumor cells from effect of EGFR
- Mutated K-ras*:* **No benefit** from cetuximab
- Wild-type K-ras*:* Cetuximab beneficial

K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757-65.

Erlotinib

Tarceva

- EGFR **tyrosine kinase inhibitor** (oral)
- Major use: non-small cell lung cancer



Erlotinib

Tarceva

- Main adverse effect: **Skin rash**
  - Acne-like eruption
  - Upper torso, face, neck
  - May be an indicator of drug effect
  - Seen with all EGFR-blocking drugs (Cetuximab)



Wikipedia/Public Domain

Imatinib

Tyrosine Kinase Inhibitor



- **Chronic myeloid leukemia**
  - Philadelphia chromosome/BCR-ABL fusion gene
  - Tyrosine kinase protein
  - Treatment: Imatinib
  - Also other TKIs: dasatinib, nilotinib, bosutinib

Imatinib

Tyrosine Kinase Inhibitor

- **Gastrointestinal stromal tumors (GIST)**
  - Rare stomach and small intestine tumors
  - Associated with c-KIT mutations
  - Treatment: surgery +/- Imatinib

KIT Mutations

- KIT (c-KIT) protein
  - Found on cell surface (CD117)
  - **Tyrosine kinase receptor**
  - Binds KIT ligand (stem cell factor)
  - Stimulates growth
- KIT mutations → cancer (proto-oncogene)
- KIT gain-of-function mutations in 95% GIST
  - CD117 positive cells

Imatinib

Adverse Effects

- **Fluid retention**
  - Usually peripheral or periobital edema
  - Sometimes pulmonary edema
- Rash



Klaus D.Peter,



James Heilman, MD/Wikipedia

Rituximab

- Monoclonal **CD20** antibody
- Leads to depletion of B cells
- Used in B-cell malignancy and autoimmune diseases

Martin Brändli /Wikipedia

Rituximab

- **B-cell malignancies**
  - Non-Hodgkin lymphoma
  - Chronic lymphocytic leukemia
- **Rheumatoid arthritis**
- **Immune thrombocytopenia (ITP)**
  - First line therapy: IVIG and steroids
  - 2nd line therapy: splenectomy
  - Alternative: Rituximab

Rituximab

Toxicity

- Rare cases of **opportunistic infections**
  - Pneumocystis jirovecii pneumonia
  - Cryptococcal meningitis
  - Cytomegalovirus colitis
  - **Progressive multifocal leukoencephalopathy (JC virus)**
- **Hepatitis B reactivation**

Tamoxifen



- Selective estrogen receptor modulator (SERM)
- Oral drug
- **Competitive antagonist** of breast estrogen receptor
  - Used in ER positive (ER+) breast cancer
  - Used as part of primary therapy
  - Also used for prevention

Tamoxifen



- Estrogen **agonist** in other tissues (bone/uterus)
- Bone: Estrogen increases bone density
- Uterus: Estrogen promotes endothelial growth

Tamoxifen

Toxicity

- **Hot flashes** (estrogen blockade)
- Increased risk of DVT/PE
  - Estrogen effects → increased clotting factors

DVT/PE

Tamoxifen

Toxicity

- Partial agonist to endometrium
  - Endometrial proliferation
  - Hyperplasia
  - Polyp formation
- May cause **endometrial cancer**
  - Associated with invasive carcinoma and uterine sarcoma
- Major risk in postmenopausal women

Raloxifene

Evista



- Also a SERM
- Estrogen actions on bone
- Anti-estrogen in breast/uterus
- **Osteoporosis** (postmenopausal women)
- Also used for prevention of breast cancer
- May cause hot flashes
- Associated with DVT/PE

Aromatase Inhibitors

Anastrozole, Letrozole, Exemestane

- ER+ breast cancer – postmenopausal women
- Block estrogen production
  - Peripheral tissues
  - Also occurs in breast cancer cells
- Inhibit aromatase enzyme
  - Androstenedione → estrone
  - Testosterone → estradiol



Anastrozole



Letrozole



Exemestane
(steroid)

Aromatase Inhibitors

Adverse Effects

- Osteoporosis (loss of estrogen)
- Increased risk of fracture



Open Stax College

Trastuzumab

Herceptin

- Monoclonal antibody to **HER-2**
  - Surface receptor
  - Activation → cell growth and proliferation
  - Overexpressed by cancer cells
  - Expressed in 25 to 30% of **breast cancers**
- Many names for HER2
  - HER2/neu
  - ERB2
  - CD340

Martin Brändli /Wikipedia

HER Family

- Human epithelial receptors
- All have inner tyrosine kinase domain
- Activation → signaling cascade → growth



Trastuzumab

Herceptin

- Improves survival in breast cancer
  - Inhibits proliferation of tumor cells
  - **Antibody-dependent cell-mediated cytotoxicity**



Satchmo2000/Wikipedia

Trastuzumab

Toxicity

- **Cardiomyopathy**
  - Usually asymptomatic ↓ LVEF
  - May lead to heart failure (dyspnea, fatigue, edema)
- Most likely due to blockade of HER2 in myocytes
  - May lead to stunning of myocardium
- Different from anthracycline cardiotoxicity
  - Not dose dependent
  - **Often reversible** when drug discontinued
  - Re-challenge often tolerated after LVEF recovery
  - Biopsy: No necrosis

Porphyrias

Jason Ryan, MD, MPH

Porphyrins

- Large nitrogen-containing molecules
- Porphrias = disorders of porphyrin synthesis
- All from **deficient enzymes** in heme synthesis
- Rarely cause anemia
- Symptoms from accumulation of porphyrins



Protoporphyrin



Heme

Heme

- Component of hemoglobin
- Mostly produced in **bone marrow and liver**
- Bone marrow: 80% of heme production
  - Used in red blood cells as hemoglobin
- **Liver**: 20% heme production
  - Used in **cytochrome P450 enzymes**



Heme

Heme Synthesis

- Begins in **mitochondria**
  - Initial ingredients: **Succinyl CoA and glycine**
  - Combined to form δ-ALA (delta-aminolevulinic acid)
  - Enzyme: **δ-ALA synthase**
  - Rate limiting step (inhibited by heme)
- Middle pathway in cytosol
- Final steps in mitochondria

Heme Synthesis



Succinyl-CoA

Lead Poisoning

δ-ALA dehydratase

δ-ALA Synthase

δ-ALA → Porphobilinogen → → → Protoporphyrin

Glycine



Sideroblastic Anemias

Fe^{2+}

Ferrochelatase

Heme

Lead Poisoning





Heme Synthesis



Porphyrias

- More than eight different types described
- Two most common (all rare):
  - Porphyria cutanea tarda
  - Acute intermittent porphyria
- Both do not cause anemia (no ↓ hemoglobin)
- Symptoms from accumulation of intermediates

Porphyria Cutanea Tarda

- Most common porphyria
- Deficient activity of UROD
  - **Uroporphyrinogen decarboxylase**
  - 5th enzyme in heme synthesis pathway

Porphyria Cutanea Tarda



Vocabulary

- Uroporphyrinogens:
  - Four propionic acid groups (3 carbons)
  - Four acetic acid groups (2 carbons)
- Different arrangements in I versus III
- Uroporphyrinogen III more common form
- Forms II, IV do not occur naturally



Uroporphyrinogen III

Vocabulary



Uroporphyrinogen III



Uroporphyrinogen I

Vocabulary

- "Porphyrinogen" = non-oxidized molecule
- "Porphyrin" = oxidized molecule (loss of hydrogen)



Uroporphyrinogen III



↓ Hydrogen
Double Bond

Uroporphyrin III

Porphyria Cutanea Tarda

- Accumulation of uroporphyrinogen
- Uroporphyrinogen oxidized → **uroporphyrin**
- Appears in plasma, excreted in urine
- Transported to skin
- Causes skin damage on exposure to light



Uroporphyrinogen

Coproporphyrinogen

Porphyria Cutanea Tarda

Symptoms

- Chronic **blistering skin lesions**
- Often accompanied by ↑ AST/ALT
- **Urine appears "tea colored"**

Porphyria Cutanea Tarda

- Decreased UROD activity is usually **acquired**
  - "Type 1" PCT has normal gene function
  - Unknown environmental trigger → ↓ UROD activity
- **Excess iron** plays central role
  - ↑ hepatic iron found on liver biopsy
  - Phlebotomy used for treatment (reduces iron stores)
  - PCT is an "iron overload syndrome"

Porphyria Cutanea Tarda

- Susceptibility factors (worsen disease):
  - Alcohol
  - Hepatitis C virus
  - HIV

Porphyria Cutanea Tarda

Diagnosis

- Measurement of **plasma or urine porphyrins**
  - Done for screening
  - Will be elevated
- Fractionation of porphyrins: ↑ **uroporphyrin**

Porphyria Cutanea Tarda

Treatment

- Phlebotomy
- Hydroxychloroquine
  - Malaria drug
  - Mechanism unclear

Porphyria Cutanea Tarda

Nosfposter2/Flikr

Acute Intermittent Porphyria

- Deficiency of enzyme PBGD
  - **Porphobilinogen deaminase**
- 3rd enzyme in heme synthesis pathway
- **Autosomal dominant** disorder
  - Low penetrance
  - Symptoms variable

Acute Intermittent Porphyria



Acute Intermittent Porphyria

- Symptoms occur as **acute, intermittent attacks**
- Occur when porphobilinogen levels rise
- δ-ALA synthase: Rate limiting enzyme
  - Feedback inhibition by heme
- Activation δ-ALA synthase → acute attack



Porphobilinogen

PBGD



Hydroxymethylbilane

Acute Intermittent Porphyria

Triggers

- **Medications**
  - Long list of meds can induce P450 system
  - Leads to ↑ heme synthesis in liver
  - Griseofulvin (antifungal)
  - Phenobarbital (seizures)
- Alcohol and smoking
- Starvation and/or reduced intake of calories
  - Low glucose activates ALA synthase

Acute Intermittent Porphyria

Mechanisms of Symptoms

- δ-ALA and Porphobilinogen: Neurotoxins
- Cerebral dysfunction
- Neuropathy
- Abdominal pain

Acute Intermittent Porphyria

Symptoms

- Five P's:
  - **Abdominal pain**
  - **Port-wine colored urine**
  - Polyneuropathy
  - Psychological disturbances
  - Precipitated by drugs

Acute Intermittent Porphyria

Symptoms

- Classic case:
  - Adult (30s-40s)
  - **Recurrent unexplained abdominal pain attacks**
  - **Abnormal color of urine**
  - Confusion and/or neuropathy

Acute Intermittent Porphyria

King George III



Wikipedia/Public Domain

Acute Intermittent Porphyria

Diagnosis

- **Best to test during an attack**
- ↑ Porphobilinogen (PBG)
- ↑ δ-ALA

Acute Intermittent Porphyria

Treatment

- Inhibition of heme production
  - **Hemin** (synthetic heme)
  - **Glucose**
- Inhibit hepatic **δ-ALA synthase** activity